566 results on '"Banerjee, SK"'
Search Results
2. Protein kinase C–mediated sodium glucose transporter 1 activation in precondition-induced cardioprotection
- Author
-
Kanwal A, Kasetti S, Putcha UK, Asthana S, and Banerjee SK
- Subjects
Ischemic-preconditioning ,Ischemia-reperfusion injury ,Phorbol-12-myristate ,oxidative stress ,SGLT1 ,Phlorizin. ,Therapeutics. Pharmacology ,RM1-950 - Abstract
Abhinav Kanwal,1,2 Sujatha Kasetti,3 Uday Kumar Putcha,4 Shailendra Asthana,2 Sanjay K Banerjee1,2 1Division of Medicinal Chemistry and Pharmacology, Indian Institute of Chemical Technology, Hyderabad, India; 2Drug Discovery Research Center (DDRC), Translational Health Science and Technology Institute (THSTI), Faridabad, Haryana, India; 3Department of Pharmacology, National Institute of Pharmaceutical Education and Research, Hyderabad, India; 4Department of Pathology, National Institute of Nutrition, Hyderabad, India Abstract: The concept of cardioprotection through preconditioning against ischemia–reperfusion (I/R) injury is well known and established. However, among different proposed mechanisms regarding the concept of ischemic preconditioning, protein kinase C (PKC)-mediated cardioprotection through ischemic preconditioning plays a key role in myocardial I/R injury. Thus, this study was designed to find the relationship between PKC and sodium glucose transporter 1 (SGLT1) in preconditioning-induced cardioprotection, which is ill reported till now. By applying a multifaceted approach, we demonstrated that PKC activates SGLT1, which curbed oxidative stress and apoptosis against I/R injury. PKC activation enhances cardiac glucose uptake through SGLT1 and seems essential in preventing I/R-induced cardiac injury, indicating a possible cross-talk between PKC and SGLT1. Keywords: ischemic preconditioning, ischemia-reperfusion injury, phorbol-12-myristate, oxidative stress, SGLT1, phlorizin
- Published
- 2016
3. Implementation of gender action plan and gender mainstreaming - an instrument of poverty reduction
- Author
-
Naher I And Banerjee SK
- Subjects
Gender Action Plan, Gender Mainstreaming, Sustainable Development Goals, Millennium Development Goals, Poverty - Abstract
Women in Bangladesh remain particularly vulnerable to living in poverty. Socially prescribed roles have limited women’s access to economic resources. Gender action plan is redressing existing gender inequalities and re-defining women’s and men’s gender roles and relations through guidance on gender mainstreaming. Main objective of gender action plan is creation of equal opportunity for women in social and economic activities. Thus, women's employment opportunities increased significantly, allowing for an improvement in the family's income level and contributing significantly to family expenses. Along with the increase in family income, women's social choices have increased with the globalization phenomenon. All out efforts, both by public and private sectors, have to be pursued to increase labor force participation by eligible women folk as the women participation is yet very low in Bangladesh which is 36.3 percent (world average is 48 percent). Gender equality is an important aspect of Sustainable Development Goals (SDGs), Goal-5 especially emphasizes on gender equality and empowerment of all women and girls. This goal encourages for adopting and strengthening sound policies and enforceable legislation for the promotion of gender equality and the empowerment of all women and girls at all levels. Government and Non-Government strategy will focus on the empowerment of women and on narrowing gender gaps through a two-pronged approach combining gender mainstreaming in all activities with complementary specific initiatives to address persistent structural constraints faced by women.
- Published
- 2022
- Full Text
- View/download PDF
4. Spatial, temporal, and demographic patterns in prevalence of chewing tobacco use in 204 countries and territories, 1990-2019: a systematic analysis from the Global Burden of Disease Study 2019
- Author
-
Kendrick, PJ, Reitsma, MB, Abbasi-Kangevari, M, Abdoli, A, Abdollahi, M, Abedi, A, Abhilash, ES, Aboyans, V, Adebayo, OM, Advani, SM, Ahinkorah, BO, Ahmad, S, Ahmadi, K, Ahmed, H, Aji, B, Akalu, Y, Akunna, CJ, Alahdab, F, Al-Aly, Z, Alanezi, FM, Alanzi, TM, Alhabib, KF, Ali, T, Alif, SM, Alipour, V, Aljunid, SM, Alomari, MA, Amin, TT, Amini, S, Amu, H, Ancuceanu, R, Anderson, JA, Andrei, CL, Andrei, T, Ansari-Moghaddam, A, Antony, B, Anvari, D, Arabloo, J, Arian, ND, Arora, M, Artanti, KD, Asmare, WN, Atnafu, DD, Ausloos, M, Awan, AT, Ayano, G, Aynalem, GL, Azari, S, Darshan, BB, Badiye, AD, Baig, AA, Banach, M, Banerjee, SK, Barker-Collo, SL, Barnighausen, TW, Barqawi, HJ, Basu, S, Bayati, M, Bazargan-Hejazi, S, Bekuma, TT, Bennett, DA, Bensenor, IM, Benzian, H, Benziger, CP, Berman, AE, Bhagavathula, AS, Bhala, N, Bhardwaj, N, Bhardwaj, P, Bhattacharyya, K, Bibi, S, Bijani, A, Biondi, A, Braithwaite, D, Brenner, H, Brunoni, AR, Burkart, K, Nagaraja, SB, Butt, ZA, dos Santos, FLC, Car, J, Carreras, G, Castaldelli-Maia, JM, Cattaruzza, MSS, Chang, J-C, Chaturvedi, P, Chen, S, Chido-Amajuoyi, OG, Chu, D-T, Chung, S-C, Ciobanu, LG, Costa, VM, Couto, RAS, Dagnew, B, Dai, X, Damasceno, AAM, Damiani, G, Dandona, L, Dandona, R, Daneshpajouhnejad, P, Gela, JD, Molla, MD, Desta, AA, Dharmaratne, SD, Dhimal, M, Eagan, AW, Kalan, ME, Edvardsson, K, Effiong, A, El Tantawi, M, Elbarazi, I, Esmaeilnejad, S, Fadhil, I, Faraon, EJA, Farwati, M, Farzadfar, F, Fazlzadeh, M, Feigin, VL, Feldman, R, Filip, I, Filippidis, F, Fischer, F, Flor, LS, Foigt, NA, Folayan, MO, Foroutan, M, Gad, MM, Gallus, S, Geberemariyam, BS, Gebregiorgis, BG, Getacher, L, Obsa, AG, Ghafourifard, M, Gheshlagh, RG, Ghashghaee, A, Ghith, N, Gil, GF, Gill, PS, Ginawi, IA, Goharinezhad, S, Golechha, M, Gopalani, SV, Gorini, G, Grivna, M, Guha, A, Guimaraes, RA, Guo, Y, Das Gupta, R, Gupta, R, Gupta, T, Gupta, V, Hafezi-Nejad, N, Haider, MR, Hamadeh, RR, Hankey, GJ, Hargono, A, Hay, S, Heidari, G, Herteliu, C, Hezam, K, Hird, TR, Holla, R, Hosseinzadeh, M, Hostiuc, M, Hostiuc, S, Househ, M, Hsiao, T, Huang, J, Ibeneme, CU, Ibitoye, SE, Ilic, IM, Ilic, MD, Inbaraj, LR, Irvani, SSN, Islam, JY, Islam, RM, Shariful Islam, Sheikh, Islami, F, Iso, H, Itumalla, R, Jaafari, J, Jain, V, Jakovljevic, M, Jang, S-I, Jayaram, S, Jeemon, P, Jha, RP, Jonas, JB, Jurisson, M, Kabir, A, Kabir, Z, Kalankesh, LR, Kanchan, T, Kandel, H, Kapoor, N, Karch, A, Karimi, SE, Kebede, KM, Kelkay, B, Kennedy, RD, Khader, YS, Khan, EA, Khayamzadeh, M, Kim, GR, Kimokoti, RW, Kivimaki, M, Kosen, S, Laxminarayana, SLK, Koyanagi, A, Krishan, K, Kugbey, N, Kumar, GA, Kumar, N, Kurmi, OP, Kusuma, D, Lacey, B, Landires, I, Lasrado, S, Lauriola, P, Lee, DW, Lee, YH, Leung, J, Li, S, Lin, H, Liu, W, Lugo, A, Kunjathur, SM, Majeed, A, Maleki, A, Malekzadeh, R, Malta, DC, Mamun, AA, Manjunatha, N, Mansouri, B, Mansournia, MA, Martini, S, Mathur, MR, Mathur, P, Mazidi, M, McKee, M, Medina-Solis, CE, Mehata, S, Mendoza, W, Menezes, RG, Miazgowski, B, Michalek, IM, Miller, TR, Mini, G, Mirica, A, Mirrakhimov, EM, Mirzaei, H, Misra, S, Mohammad, Y, Mohammadian-Hafshejani, A, Mohammed, S, Mokdad, AH, Molokhia, M, Monasta, L, Moni, MA, Moradzadeh, R, Morrison, SD, Mossie, TB, Mubarik, S, Mullany, EC, Murray, CJL, Nagaraju, SP, Naghavi, M, Naik, N, Nalini, M, Nangia, V, Naqvi, AA, Swamy, SN, Naveed, M, Nazari, J, Nduaguba, SO, Negoi, RI, Kandel, SN, Nguyen, HLT, Nigatu, YT, Nixon, MR, Nnaji, CA, Noubiap, JJ, Nowak, C, Nunez-Samudio, V, Ogbo, FA, Oguntade, AS, Oh, I-H, Olagunju, AT, Owolabi, MO, Mahesh, PA, Pakshir, K, Pana, A, Panagiotakos, D, Panda-Jonas, S, Pandey, A, Parekh, U, Park, E-C, Park, E-K, Kan, FP, Pathak, M, Pawar, S, Pestell, RG, Pham, HQ, Pinheiro, M, Pokhrel, KN, Pourshams, A, Prashant, A, Radfar, A, Rahimi-Movaghar, V, Rahman, MHU, Rahman, Muhammad, Rahmani, AM, Ram, P, Rana, J, Ranabhat, CL, Rathi, P, Rawaf, DL, Rawaf, S, Rawassizadeh, R, Renzaho, AMN, Rezapour, A, Riaz, MA, Roever, L, Ronfani, L, Roshandel, G, Roy, A, Roy, B, Saddik, B, Sahebkar, A, Salehi, S, Salimzadeh, H, Samy, AM, Sanabria, J, Santric-Milicevic, MM, Sao Jose, BP, Sathian, B, Sawhney, M, Saya, GK, Schwendicke, F, Seidu, A-A, Kumar, NS, Sepanlou, SG, Shafaat, O, Shah, SM, Shaikh, MA, Shannawaz, M, Sharafi, K, Sheikh, A, Sheikhbahaei, S, Shigematsu, M, Shiri, R, Shishani, K, Shivakumar, KM, Shivalli, S, Shrestha, R, Siabani, S, Sidemo, NB, Sigfusdottir, ID, Sigurvinsdottir, R, Silva, JP, Singh, A, Singh, JA, Singh, V, Sinha, DN, Skryabin, VY, Skryabina, AA, Soroush, A, Soyiri, IN, Sreeramareddy, CT, Stein, DJ, Steiropoulos, P, Stortecky, S, Straif, K, Abdulkader, RS, Sulo, G, Sundstrom, J, Tabuchi, T, Tadesse, EG, Tamiru, AT, Tareke, M, Tareque, MI, Tarigan, IU, Thakur, B, Thankappan, KR, Thapar, R, Tolani, MA, Tovani-Palone, MR, Tran, BX, Tripathy, JP, Tsegaye, GW, Tymeson, HD, Ullah, S, Unim, B, Updike, RL, Uthman, OA, Vacante, M, Vardavas, C, Venketasubramanian, N, Verma, M, Vidale, S, Vo, B, Vu, GT, Waheed, Y, Wang, Y, Welding, K, Werdecker, A, Whisnant, JL, Wickramasinghe, ND, Wubishet, BL, Yamagishi, K, Yano, Y, Yazdi-Feyzabadi, V, Yeshaw, Y, Yimmer, MZ, Yonemoto, N, Yousefi, Z, Yu, C, Yunusa, I, Yusefzadeh, H, Zaman, MS, Zamani, M, Zamanian, M, Zastrozhin, MS, Zastrozhina, A, Zhang, J, Zhang, Z-J, Zhong, C, Zuniga, YMH, Gakidou, E, Kendrick, PJ, Reitsma, MB, Abbasi-Kangevari, M, Abdoli, A, Abdollahi, M, Abedi, A, Abhilash, ES, Aboyans, V, Adebayo, OM, Advani, SM, Ahinkorah, BO, Ahmad, S, Ahmadi, K, Ahmed, H, Aji, B, Akalu, Y, Akunna, CJ, Alahdab, F, Al-Aly, Z, Alanezi, FM, Alanzi, TM, Alhabib, KF, Ali, T, Alif, SM, Alipour, V, Aljunid, SM, Alomari, MA, Amin, TT, Amini, S, Amu, H, Ancuceanu, R, Anderson, JA, Andrei, CL, Andrei, T, Ansari-Moghaddam, A, Antony, B, Anvari, D, Arabloo, J, Arian, ND, Arora, M, Artanti, KD, Asmare, WN, Atnafu, DD, Ausloos, M, Awan, AT, Ayano, G, Aynalem, GL, Azari, S, Darshan, BB, Badiye, AD, Baig, AA, Banach, M, Banerjee, SK, Barker-Collo, SL, Barnighausen, TW, Barqawi, HJ, Basu, S, Bayati, M, Bazargan-Hejazi, S, Bekuma, TT, Bennett, DA, Bensenor, IM, Benzian, H, Benziger, CP, Berman, AE, Bhagavathula, AS, Bhala, N, Bhardwaj, N, Bhardwaj, P, Bhattacharyya, K, Bibi, S, Bijani, A, Biondi, A, Braithwaite, D, Brenner, H, Brunoni, AR, Burkart, K, Nagaraja, SB, Butt, ZA, dos Santos, FLC, Car, J, Carreras, G, Castaldelli-Maia, JM, Cattaruzza, MSS, Chang, J-C, Chaturvedi, P, Chen, S, Chido-Amajuoyi, OG, Chu, D-T, Chung, S-C, Ciobanu, LG, Costa, VM, Couto, RAS, Dagnew, B, Dai, X, Damasceno, AAM, Damiani, G, Dandona, L, Dandona, R, Daneshpajouhnejad, P, Gela, JD, Molla, MD, Desta, AA, Dharmaratne, SD, Dhimal, M, Eagan, AW, Kalan, ME, Edvardsson, K, Effiong, A, El Tantawi, M, Elbarazi, I, Esmaeilnejad, S, Fadhil, I, Faraon, EJA, Farwati, M, Farzadfar, F, Fazlzadeh, M, Feigin, VL, Feldman, R, Filip, I, Filippidis, F, Fischer, F, Flor, LS, Foigt, NA, Folayan, MO, Foroutan, M, Gad, MM, Gallus, S, Geberemariyam, BS, Gebregiorgis, BG, Getacher, L, Obsa, AG, Ghafourifard, M, Gheshlagh, RG, Ghashghaee, A, Ghith, N, Gil, GF, Gill, PS, Ginawi, IA, Goharinezhad, S, Golechha, M, Gopalani, SV, Gorini, G, Grivna, M, Guha, A, Guimaraes, RA, Guo, Y, Das Gupta, R, Gupta, R, Gupta, T, Gupta, V, Hafezi-Nejad, N, Haider, MR, Hamadeh, RR, Hankey, GJ, Hargono, A, Hay, S, Heidari, G, Herteliu, C, Hezam, K, Hird, TR, Holla, R, Hosseinzadeh, M, Hostiuc, M, Hostiuc, S, Househ, M, Hsiao, T, Huang, J, Ibeneme, CU, Ibitoye, SE, Ilic, IM, Ilic, MD, Inbaraj, LR, Irvani, SSN, Islam, JY, Islam, RM, Shariful Islam, Sheikh, Islami, F, Iso, H, Itumalla, R, Jaafari, J, Jain, V, Jakovljevic, M, Jang, S-I, Jayaram, S, Jeemon, P, Jha, RP, Jonas, JB, Jurisson, M, Kabir, A, Kabir, Z, Kalankesh, LR, Kanchan, T, Kandel, H, Kapoor, N, Karch, A, Karimi, SE, Kebede, KM, Kelkay, B, Kennedy, RD, Khader, YS, Khan, EA, Khayamzadeh, M, Kim, GR, Kimokoti, RW, Kivimaki, M, Kosen, S, Laxminarayana, SLK, Koyanagi, A, Krishan, K, Kugbey, N, Kumar, GA, Kumar, N, Kurmi, OP, Kusuma, D, Lacey, B, Landires, I, Lasrado, S, Lauriola, P, Lee, DW, Lee, YH, Leung, J, Li, S, Lin, H, Liu, W, Lugo, A, Kunjathur, SM, Majeed, A, Maleki, A, Malekzadeh, R, Malta, DC, Mamun, AA, Manjunatha, N, Mansouri, B, Mansournia, MA, Martini, S, Mathur, MR, Mathur, P, Mazidi, M, McKee, M, Medina-Solis, CE, Mehata, S, Mendoza, W, Menezes, RG, Miazgowski, B, Michalek, IM, Miller, TR, Mini, G, Mirica, A, Mirrakhimov, EM, Mirzaei, H, Misra, S, Mohammad, Y, Mohammadian-Hafshejani, A, Mohammed, S, Mokdad, AH, Molokhia, M, Monasta, L, Moni, MA, Moradzadeh, R, Morrison, SD, Mossie, TB, Mubarik, S, Mullany, EC, Murray, CJL, Nagaraju, SP, Naghavi, M, Naik, N, Nalini, M, Nangia, V, Naqvi, AA, Swamy, SN, Naveed, M, Nazari, J, Nduaguba, SO, Negoi, RI, Kandel, SN, Nguyen, HLT, Nigatu, YT, Nixon, MR, Nnaji, CA, Noubiap, JJ, Nowak, C, Nunez-Samudio, V, Ogbo, FA, Oguntade, AS, Oh, I-H, Olagunju, AT, Owolabi, MO, Mahesh, PA, Pakshir, K, Pana, A, Panagiotakos, D, Panda-Jonas, S, Pandey, A, Parekh, U, Park, E-C, Park, E-K, Kan, FP, Pathak, M, Pawar, S, Pestell, RG, Pham, HQ, Pinheiro, M, Pokhrel, KN, Pourshams, A, Prashant, A, Radfar, A, Rahimi-Movaghar, V, Rahman, MHU, Rahman, Muhammad, Rahmani, AM, Ram, P, Rana, J, Ranabhat, CL, Rathi, P, Rawaf, DL, Rawaf, S, Rawassizadeh, R, Renzaho, AMN, Rezapour, A, Riaz, MA, Roever, L, Ronfani, L, Roshandel, G, Roy, A, Roy, B, Saddik, B, Sahebkar, A, Salehi, S, Salimzadeh, H, Samy, AM, Sanabria, J, Santric-Milicevic, MM, Sao Jose, BP, Sathian, B, Sawhney, M, Saya, GK, Schwendicke, F, Seidu, A-A, Kumar, NS, Sepanlou, SG, Shafaat, O, Shah, SM, Shaikh, MA, Shannawaz, M, Sharafi, K, Sheikh, A, Sheikhbahaei, S, Shigematsu, M, Shiri, R, Shishani, K, Shivakumar, KM, Shivalli, S, Shrestha, R, Siabani, S, Sidemo, NB, Sigfusdottir, ID, Sigurvinsdottir, R, Silva, JP, Singh, A, Singh, JA, Singh, V, Sinha, DN, Skryabin, VY, Skryabina, AA, Soroush, A, Soyiri, IN, Sreeramareddy, CT, Stein, DJ, Steiropoulos, P, Stortecky, S, Straif, K, Abdulkader, RS, Sulo, G, Sundstrom, J, Tabuchi, T, Tadesse, EG, Tamiru, AT, Tareke, M, Tareque, MI, Tarigan, IU, Thakur, B, Thankappan, KR, Thapar, R, Tolani, MA, Tovani-Palone, MR, Tran, BX, Tripathy, JP, Tsegaye, GW, Tymeson, HD, Ullah, S, Unim, B, Updike, RL, Uthman, OA, Vacante, M, Vardavas, C, Venketasubramanian, N, Verma, M, Vidale, S, Vo, B, Vu, GT, Waheed, Y, Wang, Y, Welding, K, Werdecker, A, Whisnant, JL, Wickramasinghe, ND, Wubishet, BL, Yamagishi, K, Yano, Y, Yazdi-Feyzabadi, V, Yeshaw, Y, Yimmer, MZ, Yonemoto, N, Yousefi, Z, Yu, C, Yunusa, I, Yusefzadeh, H, Zaman, MS, Zamani, M, Zamanian, M, Zastrozhin, MS, Zastrozhina, A, Zhang, J, Zhang, Z-J, Zhong, C, Zuniga, YMH, and Gakidou, E
- Published
- 2021
5. Global injury morbidity and mortality from 1990 to 2017: results from the Global Burden of Disease Study 2017
- Author
-
James, SL, Castle, CD, Dingels, ZV, Fox, JT, Hamilton, EB, Liu, Z, S Roberts, NL, Sylte, DO, Henry, NJ, LeGrand, KE, Abdelalim, A, Abdoli, A, Abdollahpour, I, Abdulkader, RS, Abedi, A, Abosetugn, AE, Abushouk, AI, Adebayo, OM, Agudelo-Botero, M, Ahmad, T, Ahmed, R, Ahmed, MB, Eddine Aichour, MT, Alahdab, F, Alamene, GM, Alanezi, FM, Alebel, A, Alema, NM, Alghnam, SA, Al-Hajj, S, Ali, BA, Ali, S, Alikhani, M, Alinia, C, Alipour, V, Aljunid, SM, Almasi-Hashiani, A, Almasri, NA, Altirkawi, K, Abdeldayem Amer, YS, Amini, S, Loreche Amit, AM, Andrei, CL, Ansari-Moghaddam, A, T Antonio, CA, Yaw Appiah, SC, Arabloo, J, Arab-Zozani, M, Arefi, Z, Aremu, O, Ariani, F, Arora, A, Asaad, M, Asghari, B, Awoke, N, Ayala Quintanilla, BP, Ayano, G, Ayanore, MA, Azari, S, Azarian, G, Badawi, A, Badiye, AD, Bagli, E, Baig, AA, Bairwa, M, Bakhtiari, A, Balachandran, A, Banach, M, Banerjee, SK, Banik, PC, Banstola, A, Barker-Collo, SL, Bärnighausen, TW, Barrero, LH, Barzegar, A, Bayati, M, Baye, BA, Bedi, N, Behzadifar, M, Bekuma, TT, Belete, H, Benjet, C, Bennett, DA, Bensenor, IM, Berhe, K, Bhardwaj, P, Bhat, AG, Bhattacharyya, K, Bibi, S, Bijani, A, Bin Sayeed, MS, Borges, G, Borzì, AM, Boufous, S, Brazinova, A, Briko, NI, Budhathoki, SS, Car, J, Cárdenas, R, Carvalho, F, Castaldelli-Maia, JM, Castañeda-Orjuela, CA, Castelpietra, G, Catalá-López, F, Cerin, E, Chandan, JS, Chanie, WF, Chattu, SK, Chattu, VK, Chatziralli, I, Chaudhary, N, Cho, DY, Kabir Chowdhury, MA, Chu, D-T, Colquhoun, SM, Constantin, M-M, Costa, VM, Damiani, G, Daryani, A, Dávila-Cervantes, CA, Demeke, FM, Demis, AB, Demoz, GT, Demsie, DG, Derakhshani, A, Deribe, K, Desai, R, Nasab, MD, da Silva, DD, Dibaji Forooshani, ZS, Doyle, KE, Driscoll, TR, Dubljanin, E, Adema, BD, Eagan, AW, Eftekhari, A, Ehsani-Chimeh, E, Sayed Zaki, ME, Elemineh, DA, El-Jaafary, SI, El-Khatib, Z, Ellingsen, CL, Emamian, MH, Endalew, DA, Eskandarieh, S, Faris, PS, Faro, A, Farzadfar, F, Fatahi, Y, Fekadu, W, Ferede, TY, Fereshtehnejad, S-M, Fernandes, E, Ferrara, P, Feyissa, GT, Filip, I, Fischer, F, Folayan, MO, Foroutan, M, Francis, JM, Franklin, RC, Fukumoto, T, Geberemariyam, BS, Gebre, AK, Gebremedhin, KB, Gebremeskel, GG, Gebremichael, B, Gedefaw, GA, Geta, B, Ghafourifard, M, Ghamari, F, Ghashghaee, A, Gholamian, A, Gill, TK, Goulart, AC, Grada, A, Grivna, M, Mohialdeen Gubari, MI, Guimarães, RA, Guo, Y, Gupta, G, Haagsma, JA, Hafezi-Nejad, N, Bidgoli, HH, Hall, BJ, Hamadeh, RR, Hamidi, S, Haro, JM, Hasan, MM, Hasanzadeh, A, Hassanipour, S, Hassankhani, H, Hassen, HY, Havmoeller, R, Hayat, K, Hendrie, D, Heydarpour, F, Híjar, M, Ho, HC, Hoang, CL, Hole, MK, Holla, R, Hossain, N, Hosseinzadeh, M, Hostiuc, S, Hu, G, Ibitoye, SE, Ilesanmi, OS, Ilic, I, Ilic, MD, Inbaraj, LR, Indriasih, E, Naghibi Irvani, SS, Shariful Islam, SM, Islam, MM, Ivers, RQ, Jacobsen, KH, Jahani, MA, Jahanmehr, N, Jakovljevic, M, Jalilian, F, Jayaraman, S, Jayatilleke, AU, Jha, RP, John-Akinola, YO, Jonas, JB, Joseph, N, Joukar, F, Jozwiak, JJ, Jungari, SB, Jürisson, M, Kabir, A, Kadel, R, Kahsay, A, Kalankesh, LR, Kalhor, R, Kamil, TA, Kanchan, T, Kapoor, N, Karami, M, Kasaeian, A, Kassaye, HG, Kavetskyy, T, Kebede, HK, Keiyoro, PN, Kelbore, AG, Kelkay, B, Khader, YS, Khafaie, MA, Khalid, N, Khalil, IA, Khalilov, R, Khammarnia, M, Khan, EA, Khan, M, Khanna, T, Khazaie, H, Shadmani, FK, Khundkar, R, Kiirithio, DN, Kim, Y-E, Kim, D, Kim, YJ, Kisa, A, Kisa, S, Komaki, H, M Kondlahalli, SK, Korshunov, VA, Koyanagi, A, G Kraemer, MU, Krishan, K, Bicer, BK, Kugbey, N, Kumar, V, Kumar, N, Kumar, GA, Kumar, M, Kumaresh, G, Kurmi, OP, Kuti, O, Vecchia, CL, Lami, FH, Lamichhane, P, Lang, JJ, Lansingh, VC, Laryea, DO, Lasrado, S, Latifi, A, Lauriola, P, Leasher, JL, Huey Lee, SW, Lenjebo, TL, Levi, M, Li, S, Linn, S, Liu, X, Lopez, AD, Lotufo, PA, Lunevicius, R, Lyons, RA, Madadin, M, El Razek, MMA, Mahotra, NB, Majdan, M, Majeed, A, Malagon-Rojas, JN, Maled, V, Malekzadeh, R, Malta, DC, Manafi, N, Manafi, A, Manda, A-L, Manjunatha, N, Mansour-Ghanaei, F, Mansouri, B, Mansournia, MA, Maravilla, JC, March, LM, Mason-Jones, AJ, Masoumi, SZ, Massenburg, BB, Maulik, PK, Meles, GG, Melese, A, Melketsedik, ZA, N Memiah, PT, Mendoza, W, Menezes, RG, Mengesha, MB, Mengesha, MM, Meretoja, TJ, Meretoja, A, Merie, HE, Mestrovic, T, Miazgowski, B, Miazgowski, T, Miller, TR, Mini, GK, Mirica, A, Mirrakhimov, EM, Mirzaei-Alavijeh, M, Mithra, P, Moazen, B, Moghadaszadeh, M, Mohamadi, E, Mohammad, Y, Mohammad, KA, Darwesh, AM, Gholi Mezerji, NM, Mohammadian-Hafshejani, A, Mohammadoo-Khorasani, M, Mohammadpourhodki, R, Mohammed, S, Mohammed, JA, Mohebi, F, Molokhia, M, Monasta, L, Moodley, Y, Moosazadeh, M, Moradi, M, Moradi, G, Moradi-Lakeh, M, Moradpour, F, Morawska, L, Velásquez, IM, Morisaki, N, Morrison, SD, Mossie, TB, Muluneh, AG, Murthy, S, Musa, KI, Mustafa, G, Nabhan, AF, Nagarajan, AJ, Naik, G, Naimzada, MD, Najafi, F, Nangia, V, Nascimento, BR, Naserbakht, M, Nayak, V, Ndwandwe, DE, Negoi, I, Ngunjiri, JW, Nguyen, CT, Thi Nguyen, HL, Nikbakhsh, R, Anggraini Ningrum, DN, Nnaji, CA, Nyasulu, PS, Ogbo, FA, Oghenetega, OB, Oh, I-H, Okunga, EW, Olagunju, AT, Olagunju, TO, Bali, AO, Onwujekwe, OE, Asante, KO, Orpana, HM, Ota, E, Otstavnov, N, Otstavnov, SS, A, MP, Padubidri, JR, Pakhale, S, Pakshir, K, Panda-Jonas, S, Park, E-K, Patel, SK, Pathak, A, Pati, S, Patton, GC, Paulos, K, Peden, AE, Filipino Pepito, VC, Pereira, J, Pham, HQ, Phillips, MR, Pinheiro, M, Polibin, RV, Polinder, S, Poustchi, H, Prakash, S, Angga Pribadi, DR, Puri, P, Syed, ZQ, Rabiee, M, Rabiee, N, Radfar, A, Rafay, A, Rafiee, A, Rafiei, A, Rahim, F, Rahimi, S, Rahimi-Movaghar, V, Rahman, MA, Rajabpour-Sanati, A, Rajati, F, Rakovac, I, Ranganathan, K, Rao, SJ, Rashedi, V, Rastogi, P, Rathi, P, Rawaf, S, Rawal, L, Rawassizadeh, R, Renjith, V, N Renzaho, AM, Resnikoff, S, Rezapour, A, Ribeiro, AI, Rickard, J, Rios González, CM, Ronfani, L, Roshandel, G, Saad, AM, Sabde, YD, Sabour, S, Saddik, B, Safari, S, Safari-Faramani, R, Safarpour, H, Safdarian, M, Sajadi, SM, Salamati, P, Salehi, F, Zahabi, SS, Rashad Salem, MR, Salem, H, Salman, O, Salz, I, Samy, AM, Sanabria, J, Riera, LS, Santric Milicevic, MM, Sarker, AR, Sarveazad, A, Sathian, B, Sawhney, M, Sawyer, SM, Saxena, S, Sayyah, M, Schwebel, DC, Seedat, S, Senthilkumaran, S, Sepanlou, SG, Seyedmousavi, S, Sha, F, Shaahmadi, F, Shahabi, S, Shaikh, MA, Shams-Beyranvand, M, Shamsizadeh, M, Sharif-Alhoseini, M, Sharifi, H, Sheikh, A, Shigematsu, M, Shin, JI, Shiri, R, Siabani, S, Sigfusdottir, ID, Singh, PK, Singh, JA, Sinha, DN, Smarandache, C-G, R Smith, EU, Soheili, A, Soleymani, B, Soltanian, AR, Soriano, JB, Sorrie, MB, Soyiri, IN, Stein, DJ, Stokes, MA, Sufiyan, MB, Rasul Suleria, HA, Sykes, BL, Tabarés-Seisdedos, R, Tabb, KM, Taddele, BW, Tadesse, DB, Tamiru, AT, Tarigan, IU, Tefera, YM, Tehrani-Banihashemi, A, Tekle, MG, Tekulu, GH, Tesema, AK, Tesfay, BE, Thapar, R, Tilahune, AB, Tlaye, KG, Tohidinik, HR, Topor-Madry, R, Tran, BX, Tran, KB, Tripathy, JP, Tsai, AC, Car, LT, Ullah, S, Ullah, I, Umar, M, Unnikrishnan, B, Upadhyay, E, Uthman, OA, Valdez, PR, Vasankari, TJ, Venketasubramanian, N, Violante, FS, Vlassov, V, Waheed, Y, Weldesamuel, GT, Werdecker, A, Wiangkham, T, Wolde, HF, Woldeyes, DH, Wondafrash, DZ, Wondmeneh, TG, Wondmieneh, AB, Wu, A-M, Yadav, R, Yadollahpour, A, Yano, Y, Yaya, S, Yazdi-Feyzabadi, V, Yip, P, Yisma, E, Yonemoto, N, Yoon, S-J, Youm, Y, Younis, MZ, Yousefi, Z, Yu, Y, Yu, C, Yusefzadeh, H, Moghadam, TZ, Zaidi, Z, Zaman, SB, Zamani, M, Zamanian, M, Zandian, H, Zarei, A, Zare, F, Zhang, Z-J, Zhang, Y, Zodpey, S, Dandona, L, Dandona, R, Degenhardt, L, Dharmaratne, SD, Hay, SI, Mokdad, AH, Reiner, RC, Sartorius, B, and Vos, T
- Subjects
Life Expectancy ,Incidence ,burden of disease, descriptive epidemiology, global ,Humans ,Wounds and Injuries ,Public Health ,Quality-Adjusted Life Years ,Morbidity ,Global Health ,1106 Human Movement and Sports Sciences, 1117 Public Health and Health Services, 1701 Psychology ,Global Burden of Disease - Abstract
BACKGROUND: Past research in population health trends has shown that injuries form a substantial burden of population health loss. Regular updates to injury burden assessments are critical. We report Global Burden of Disease (GBD) 2017 Study estimates on morbidity and mortality for all injuries.; METHODS: We reviewed results for injuries from the GBD 2017 study. GBD 2017 measured injury-specific mortality and years of life lost (YLLs) using the Cause of Death Ensemble model. To measure non-fatal injuries, GBD 2017 modelled injury-specific incidence and converted this to prevalence and years lived with disability (YLDs). YLLs and YLDs were summed to calculate disability-adjusted life years (DALYs).; FINDINGS: In 1990, there were 4 260 493 (4 085 700 to 4 396 138) injury deaths, which increased to 4 484 722 (4 332 010 to 4 585 554) deaths in 2017, while age-standardised mortality decreased from 1079 (1073 to 1086) to 738 (730 to 745) per 100000. In 1990, there were 354064302 (95% uncertainty interval: 338174876 to 371 610 802) new cases of injury globally, which increased to 520 710 288 (493 430 247 to 547 988 635) new cases in 2017. During this time, age-standardised incidence decreased non-significantly from 6824 (6534 to 7147) to 6763 (6412 to 7118) per 100000. Between 1990 and 2017, age-standardised DALYs decreased from 4947 (4655 to 5233) per 100000 to 3267 (3058 to 3505).; INTERPRETATION: Injuries are an important cause of health loss globally, though mortality has declined between 1990 and 2017. Future research in injury burden should focus on prevention in high-burden populations, improving data collection and ensuring access to medical care. © Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY. Published by BMJ.
- Published
- 2020
6. Estimating global injuries morbidity and mortality: Methods and data used in the Global Burden of Disease 2017 study
- Author
-
James, SL, Castle, CD, Dingels, ZV, Fox, JT, Hamilton, EB, Liu, Z, Roberts, NLS, Sylte, DO, Bertolacci, GJ, Cunningham, M, Henry, NJ, Legrand, KE, Abdelalim, A, Abdollahpour, I, Abdulkader, RS, Abedi, A, Abegaz, KH, Abosetugn, AE, Abushouk, AI, Adebayo, OM, Adsuar, JC, Advani, SM, Agudelo-Botero, M, Ahmad, T, Ahmed, MB, Ahmed, R, Aichour, MTE, Alahdab, F, Alanezi, FM, Alema, NM, Alemu, BW, Alghnam, SA, Ali, BA, Ali, S, Alinia, C, Alipour, V, Aljunid, SM, Almasi-Hashiani, A, Almasri, NA, Altirkawi, K, Amer, YSA, Andrei, CL, Ansari-Moghaddam, A, Antonio, CAT, Anvari, D, Appiah, SCY, Arabloo, J, Arab-Zozani, M, Arefi, Z, Aremu, O, Ariani, F, Arora, A, Asaad, M, Quintanilla, BPA, Ayano, G, Ayanore, MA, Azarian, G, Badawi, A, Badiye, AD, Baig, AA, Bairwa, M, Bakhtiari, A, Balachandran, A, Banach, M, Banerjee, SK, Banik, PC, Banstola, A, Barker-Collo, SL, Bärnighausen, TW, Barzegar, A, Bayati, M, Bazargan-Hejazi, S, Bedi, N, Behzadifar, M, Belete, H, Bennett, DA, Bensenor, IM, Berhe, K, Bhagavathula, AS, Bhardwaj, P, Bhat, AG, Bhattacharyya, K, Bhutta, ZA, Bibi, S, Bijani, A, Boloor, A, Borges, G, Borschmann, R, Borzì, AM, Boufous, S, Braithwaite, D, Briko, NI, Brugha, T, Budhathoki, SS, Car, J, Cárdenas, R, Carvalho, F, Castaldelli-Maia, JM, Castañeda-Orjuela, CA, Castelpietra, G, James, SL, Castle, CD, Dingels, ZV, Fox, JT, Hamilton, EB, Liu, Z, Roberts, NLS, Sylte, DO, Bertolacci, GJ, Cunningham, M, Henry, NJ, Legrand, KE, Abdelalim, A, Abdollahpour, I, Abdulkader, RS, Abedi, A, Abegaz, KH, Abosetugn, AE, Abushouk, AI, Adebayo, OM, Adsuar, JC, Advani, SM, Agudelo-Botero, M, Ahmad, T, Ahmed, MB, Ahmed, R, Aichour, MTE, Alahdab, F, Alanezi, FM, Alema, NM, Alemu, BW, Alghnam, SA, Ali, BA, Ali, S, Alinia, C, Alipour, V, Aljunid, SM, Almasi-Hashiani, A, Almasri, NA, Altirkawi, K, Amer, YSA, Andrei, CL, Ansari-Moghaddam, A, Antonio, CAT, Anvari, D, Appiah, SCY, Arabloo, J, Arab-Zozani, M, Arefi, Z, Aremu, O, Ariani, F, Arora, A, Asaad, M, Quintanilla, BPA, Ayano, G, Ayanore, MA, Azarian, G, Badawi, A, Badiye, AD, Baig, AA, Bairwa, M, Bakhtiari, A, Balachandran, A, Banach, M, Banerjee, SK, Banik, PC, Banstola, A, Barker-Collo, SL, Bärnighausen, TW, Barzegar, A, Bayati, M, Bazargan-Hejazi, S, Bedi, N, Behzadifar, M, Belete, H, Bennett, DA, Bensenor, IM, Berhe, K, Bhagavathula, AS, Bhardwaj, P, Bhat, AG, Bhattacharyya, K, Bhutta, ZA, Bibi, S, Bijani, A, Boloor, A, Borges, G, Borschmann, R, Borzì, AM, Boufous, S, Braithwaite, D, Briko, NI, Brugha, T, Budhathoki, SS, Car, J, Cárdenas, R, Carvalho, F, Castaldelli-Maia, JM, Castañeda-Orjuela, CA, and Castelpietra, G
- Abstract
Background: While there is a long history of measuring death and disability from injuries, modern research methods must account for the wide spectrum of disability that can occur in an injury, and must provide estimates with sufficient demographic, geographical and temporal detail to be useful for policy makers. The Global Burden of Disease (GBD) 2017 study used methods to provide highly detailed estimates of global injury burden that meet these criteria. Methods: In this study, we report and discuss the methods used in GBD 2017 for injury morbidity and mortality burden estimation. In summary, these methods included estimating cause-specific mortality for every cause of injury, and then estimating incidence for every cause of injury. Non-fatal disability for each cause is then calculated based on the probabilities of suffering from different types of bodily injury experienced. Results: GBD 2017 produced morbidity and mortality estimates for 38 causes of injury. Estimates were produced in terms of incidence, prevalence, years lived with disability, cause-specific mortality, years of life lost and disability-adjusted life-years for a 28-year period for 22 age groups, 195 countries and both sexes. Conclusions: GBD 2017 demonstrated a complex and sophisticated series of analytical steps using the largest known database of morbidity and mortality data on injuries. GBD 2017 results should be used to help inform injury prevention policy making and resource allocation. We also identify important avenues for improving injury burden estimation in the future.
- Published
- 2020
7. Measuring universal health coverage based on an index of effective coverage of health services in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019
- Author
-
Lozano, R, Fullman, N, Mumford, JE, Knight, M, Barthelemy, CM, Abbafati, C, Abbastabar, H, Abd-Allah, F, Abdollahi, M, Abedi, A, Abolhassani, H, Abosetugn, AE, Abreu, LG, Abrigo, MRM, Abu Haimed, AK, Abushouk, AI, Adabi, M, Adebayo, OM, Adekanmbi, V, Adelson, J, Adetokunboh, OO, Adham, D, Advani, SM, Afshin, A, Agarwal, G, Agasthi, P, Aghamir, SMK, Agrawal, A, Ahmad, T, Akinyemi, RO, Alahdab, F, Al-Aly, Z, Alam, K, Albertson, SB, Alemu, YM, Alhassan, RK, Ali, M, Ali, S, Alipour, V, Aljunid, SM, Alla, F, Almadi, MAH, Almasi, A, Almasi-Hashiani, A, Almasri, NA, Al-Mekhlafi, HM, Almulhim, AM, Alonso, J, Al-Raddadi, RM, Altirkawi, KA, Alvis-Guzman, N, Alvis-Zakzuk, NJ, Amini, S, Amini-Rarani, M, Amiri, F, Amit, AML, Amugsi, DA, Ancuceanu, R, Anderlini, D, Andrei, CL, Androudi, S, Ansari, F, Ansari-Moghaddam, A, Antonio, CAT, Antony, CM, Antriyandarti, E, Anvari, D, Anwer, R, Arabloo, J, Arab-Zozani, M, Aravkin, AY, Aremu, O, Ärnlöv, J, Asaad, M, Asadi-Aliabadi, M, Asadi-Pooya, AA, Athari, SS, Atout, MMDW, Ausloos, M, Avila-Burgos, L, Ayala Quintanilla, BP, Ayano, G, Ayanore, MA, Aynalem, YA, Aynalem, GL, Ayza, MA, Azari, S, Azzopardi, PS, B, DB, Babaee, E, Badiye, AD, Bahrami, MA, Baig, AA, Bakhshaei, MH, Bakhtiari, A, Bakkannavar, SM, Balachandran, A, Banach, M, Banerjee, SK, Banik, PC, Lozano, R, Fullman, N, Mumford, JE, Knight, M, Barthelemy, CM, Abbafati, C, Abbastabar, H, Abd-Allah, F, Abdollahi, M, Abedi, A, Abolhassani, H, Abosetugn, AE, Abreu, LG, Abrigo, MRM, Abu Haimed, AK, Abushouk, AI, Adabi, M, Adebayo, OM, Adekanmbi, V, Adelson, J, Adetokunboh, OO, Adham, D, Advani, SM, Afshin, A, Agarwal, G, Agasthi, P, Aghamir, SMK, Agrawal, A, Ahmad, T, Akinyemi, RO, Alahdab, F, Al-Aly, Z, Alam, K, Albertson, SB, Alemu, YM, Alhassan, RK, Ali, M, Ali, S, Alipour, V, Aljunid, SM, Alla, F, Almadi, MAH, Almasi, A, Almasi-Hashiani, A, Almasri, NA, Al-Mekhlafi, HM, Almulhim, AM, Alonso, J, Al-Raddadi, RM, Altirkawi, KA, Alvis-Guzman, N, Alvis-Zakzuk, NJ, Amini, S, Amini-Rarani, M, Amiri, F, Amit, AML, Amugsi, DA, Ancuceanu, R, Anderlini, D, Andrei, CL, Androudi, S, Ansari, F, Ansari-Moghaddam, A, Antonio, CAT, Antony, CM, Antriyandarti, E, Anvari, D, Anwer, R, Arabloo, J, Arab-Zozani, M, Aravkin, AY, Aremu, O, Ärnlöv, J, Asaad, M, Asadi-Aliabadi, M, Asadi-Pooya, AA, Athari, SS, Atout, MMDW, Ausloos, M, Avila-Burgos, L, Ayala Quintanilla, BP, Ayano, G, Ayanore, MA, Aynalem, YA, Aynalem, GL, Ayza, MA, Azari, S, Azzopardi, PS, B, DB, Babaee, E, Badiye, AD, Bahrami, MA, Baig, AA, Bakhshaei, MH, Bakhtiari, A, Bakkannavar, SM, Balachandran, A, Banach, M, Banerjee, SK, and Banik, PC
- Abstract
Background: Achieving universal health coverage (UHC) involves all people receiving the health services they need, of high quality, without experiencing financial hardship. Making progress towards UHC is a policy priority for both countries and global institutions, as highlighted by the agenda of the UN Sustainable Development Goals (SDGs) and WHO's Thirteenth General Programme of Work (GPW13). Measuring effective coverage at the health-system level is important for understanding whether health services are aligned with countries' health profiles and are of sufficient quality to produce health gains for populations of all ages. Methods: Based on the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2019, we assessed UHC effective coverage for 204 countries and territories from 1990 to 2019. Drawing from a measurement framework developed through WHO's GPW13 consultation, we mapped 23 effective coverage indicators to a matrix representing health service types (eg, promotion, prevention, and treatment) and five population-age groups spanning from reproductive and newborn to older adults (≥65 years). Effective coverage indicators were based on intervention coverage or outcome-based measures such as mortality-to-incidence ratios to approximate access to quality care; outcome-based measures were transformed to values on a scale of 0–100 based on the 2·5th and 97·5th percentile of location-year values. We constructed the UHC effective coverage index by weighting each effective coverage indicator relative to its associated potential health gains, as measured by disability-adjusted life-years for each location-year and population-age group. For three tests of validity (content, known-groups, and convergent), UHC effective coverage index performance was generally better than that of other UHC service coverage indices from WHO (ie, the current metric for SDG indicator 3.8.1 on UHC service coverage), the World Bank, and GBD 2017. We quantified frontiers of UHC e
- Published
- 2020
8. Health sector spending and spending on HIV/AIDS, tuberculosis, and malaria, and development assistance for health: progress towards Sustainable Development Goal 3
- Author
-
Micah, AE, Su, Y, Bachmeier, SD, Chapin, A, Cogswell, IE, Crosby, SW, Cunningham, B, Harle, AC, Maddison, ER, Moitra, M, Sahu, M, Schneider, MT, Simpson, KE, Stutzman, HN, Tsakalos, G, Zende, RR, Zlavog, BS, Abbafati, C, Abebo, ZH, Abolhassani, H, Abrigo, MRM, Ahmed, MB, Akinyemi, RO, Alam, K, Ali, S, Alinia, C, Alipour, V, Aljunid, SM, Almasi, A, Alvis-Guzman, N, Ancuceanu, R, Andrei, T, Andrei, CL, Anjomshoa, M, Antonio, CAT, Arabloo, J, Arab-Zozani, M, Aremu, O, Atnafu, DD, Ausloos, M, Avila-Burgos, L, Ayanore, MA, Azari, S, Babalola, TK, Bagherzadeh, M, Baig, AA, Bakhtiari, A, Banach, M, Banerjee, SK, Barnighausen, TW, Basu, S, Baune, BT, Bayati, M, Berman, AE, Bhageerathy, R, Bhardwaj, P, Bohluli, M, Busse, R, Cahuana-Hurtado, L, Camera, LLAA, Castaneda-Orjuela, CA, Catala-Lopez, F, Cevik, M, Chattu, VK, Dandona, L, Dandona, R, Dianatinasab, M, Hoa, TD, Doshmangir, L, El Tantawi, M, Eskandarieh, S, Esmaeilzadeh, F, Faraj, A, Farzadfar, F, Fischer, F, Foigt, NA, Fullman, N, Gad, MM, Ghafourifard, M, Ghashghaee, A, Gholamian, A, Goharinezhad, S, Grada, A, Bidgoli, HH, Hamidi, S, Harb, HL, Hasanpoor, E, Hay, SI, Hendrie, D, Henry, NJ, Herteliu, C, Hole, MK, Hosseinzadeh, M, Hostiuc, S, Huda, TM, Humayun, A, Hwang, B-F, Ilesanmi, OS, Iqbal, U, Irvani, SS, Islam, SMS, Islam, MM, Jahani, MA, Jakovljevic, M, James, SL, Javaheri, Z, Jonas, JB, Joukar, F, Jozwiak, JJ, Jurisson, M, Kalhor, R, Matin, BK, Karimi, SE, Kayode, GA, Karyani, AK, Kinfu, Y, Kisa, A, Kohler, S, Komaki, H, Kosen, S, Kotlo, A, Koyanagi, A, Kumar, GA, Kusuma, D, Lansingh, VC, Larsson, AO, Lasrado, S, Lee, SWH, Lim, L-L, Lozano, R, Abd El Razek, HM, Mahdavi, MM, Maleki, S, Malekzadeh, R, Mansour-Ghanaei, F, Mansournia, MA, Mantovani, LG, Martinez, G, Masoumi, SZ, Massenburg, BB, Menezes, RG, Mengesha, EW, Meretoja, TJ, Meretoja, A, Mestrovic, T, Kostova, NM, Miller, TR, Mirica, A, Mirrakhimov, EM, Moghadaszadeh, M, Mohajer, B, Mohamadi, E, Darwesh, AM, Mohammadian-Hafshejani, A, Mohammadpourhodki, R, Mohammed, S, Mohebi, F, Mokdad, AH, Morrison, SD, Mosser, JF, Mousavi, SM, Muriithi, MK, Muthupandian, S, Myint, C-Y, Naderi, M, Nagarajan, AJ, Cuong, TN, Huong, LTN, Nonvignon, J, Noubiap, JJ, Oh, I-H, Olagunju, AT, Olusanya, JO, Olusanya, BO, Bali, AO, Onwujekwe, OE, Otstavnov, SS, Otstavnov, N, Owolabi, MO, Padubidri, JR, Palladino, R, Panda-Jonas, S, Pandey, A, Postma, MJ, Prada, SI, Pribadi, DRA, Rabiee, M, Rabiee, N, Rahim, F, Ranabhat, CL, Rao, SJ, Rathi, P, Rawaf, S, Rawaf, DL, Rawal, L, Rawassizadeh, R, Rezapour, A, Sabour, S, Sahraian, MA, Salman, OM, Salomon, JA, Samy, AM, Sanabria, J, Santos, JV, Milicevic, MMS, Jose, BPS, Savic, M, Schwendicke, F, Senthilkumaran, S, Sepanlou, SG, Servan-Mori, E, Setayesh, H, Shaikh, MA, Sheikh, A, Shibuya, K, Shrime, MG, Simonetti, B, Singh, JA, Singh, P, Skryabin, VY, Soheili, A, Soltani, S, Stefan, SC, Tabares-Seisdedos, R, Topor-Madry, R, Tovani-Palone, MR, Tran, BX, Travillian, R, Undurraga, EA, Valdez, PR, van Boven, JFM, Vasankari, TJ, Violante, FS, Vlassov, V, Vos, T, Wolfe, CDA, Wu, J, Yaya, S, Yazdi-Feyzabadi, V, Yip, P, Yonemoto, N, Younis, MZ, Yu, C, Zaidi, Z, Bin Zaman, S, Zastrozhin, MS, Zhang, Z-J, Zhao, Y, Murray, CJL, Dieleman, JL, Micah, AE, Su, Y, Bachmeier, SD, Chapin, A, Cogswell, IE, Crosby, SW, Cunningham, B, Harle, AC, Maddison, ER, Moitra, M, Sahu, M, Schneider, MT, Simpson, KE, Stutzman, HN, Tsakalos, G, Zende, RR, Zlavog, BS, Abbafati, C, Abebo, ZH, Abolhassani, H, Abrigo, MRM, Ahmed, MB, Akinyemi, RO, Alam, K, Ali, S, Alinia, C, Alipour, V, Aljunid, SM, Almasi, A, Alvis-Guzman, N, Ancuceanu, R, Andrei, T, Andrei, CL, Anjomshoa, M, Antonio, CAT, Arabloo, J, Arab-Zozani, M, Aremu, O, Atnafu, DD, Ausloos, M, Avila-Burgos, L, Ayanore, MA, Azari, S, Babalola, TK, Bagherzadeh, M, Baig, AA, Bakhtiari, A, Banach, M, Banerjee, SK, Barnighausen, TW, Basu, S, Baune, BT, Bayati, M, Berman, AE, Bhageerathy, R, Bhardwaj, P, Bohluli, M, Busse, R, Cahuana-Hurtado, L, Camera, LLAA, Castaneda-Orjuela, CA, Catala-Lopez, F, Cevik, M, Chattu, VK, Dandona, L, Dandona, R, Dianatinasab, M, Hoa, TD, Doshmangir, L, El Tantawi, M, Eskandarieh, S, Esmaeilzadeh, F, Faraj, A, Farzadfar, F, Fischer, F, Foigt, NA, Fullman, N, Gad, MM, Ghafourifard, M, Ghashghaee, A, Gholamian, A, Goharinezhad, S, Grada, A, Bidgoli, HH, Hamidi, S, Harb, HL, Hasanpoor, E, Hay, SI, Hendrie, D, Henry, NJ, Herteliu, C, Hole, MK, Hosseinzadeh, M, Hostiuc, S, Huda, TM, Humayun, A, Hwang, B-F, Ilesanmi, OS, Iqbal, U, Irvani, SS, Islam, SMS, Islam, MM, Jahani, MA, Jakovljevic, M, James, SL, Javaheri, Z, Jonas, JB, Joukar, F, Jozwiak, JJ, Jurisson, M, Kalhor, R, Matin, BK, Karimi, SE, Kayode, GA, Karyani, AK, Kinfu, Y, Kisa, A, Kohler, S, Komaki, H, Kosen, S, Kotlo, A, Koyanagi, A, Kumar, GA, Kusuma, D, Lansingh, VC, Larsson, AO, Lasrado, S, Lee, SWH, Lim, L-L, Lozano, R, Abd El Razek, HM, Mahdavi, MM, Maleki, S, Malekzadeh, R, Mansour-Ghanaei, F, Mansournia, MA, Mantovani, LG, Martinez, G, Masoumi, SZ, Massenburg, BB, Menezes, RG, Mengesha, EW, Meretoja, TJ, Meretoja, A, Mestrovic, T, Kostova, NM, Miller, TR, Mirica, A, Mirrakhimov, EM, Moghadaszadeh, M, Mohajer, B, Mohamadi, E, Darwesh, AM, Mohammadian-Hafshejani, A, Mohammadpourhodki, R, Mohammed, S, Mohebi, F, Mokdad, AH, Morrison, SD, Mosser, JF, Mousavi, SM, Muriithi, MK, Muthupandian, S, Myint, C-Y, Naderi, M, Nagarajan, AJ, Cuong, TN, Huong, LTN, Nonvignon, J, Noubiap, JJ, Oh, I-H, Olagunju, AT, Olusanya, JO, Olusanya, BO, Bali, AO, Onwujekwe, OE, Otstavnov, SS, Otstavnov, N, Owolabi, MO, Padubidri, JR, Palladino, R, Panda-Jonas, S, Pandey, A, Postma, MJ, Prada, SI, Pribadi, DRA, Rabiee, M, Rabiee, N, Rahim, F, Ranabhat, CL, Rao, SJ, Rathi, P, Rawaf, S, Rawaf, DL, Rawal, L, Rawassizadeh, R, Rezapour, A, Sabour, S, Sahraian, MA, Salman, OM, Salomon, JA, Samy, AM, Sanabria, J, Santos, JV, Milicevic, MMS, Jose, BPS, Savic, M, Schwendicke, F, Senthilkumaran, S, Sepanlou, SG, Servan-Mori, E, Setayesh, H, Shaikh, MA, Sheikh, A, Shibuya, K, Shrime, MG, Simonetti, B, Singh, JA, Singh, P, Skryabin, VY, Soheili, A, Soltani, S, Stefan, SC, Tabares-Seisdedos, R, Topor-Madry, R, Tovani-Palone, MR, Tran, BX, Travillian, R, Undurraga, EA, Valdez, PR, van Boven, JFM, Vasankari, TJ, Violante, FS, Vlassov, V, Vos, T, Wolfe, CDA, Wu, J, Yaya, S, Yazdi-Feyzabadi, V, Yip, P, Yonemoto, N, Younis, MZ, Yu, C, Zaidi, Z, Bin Zaman, S, Zastrozhin, MS, Zhang, Z-J, Zhao, Y, Murray, CJL, and Dieleman, JL
- Abstract
BACKGROUND: Sustainable Development Goal (SDG) 3 aims to "ensure healthy lives and promote well-being for all at all ages". While a substantial effort has been made to quantify progress towards SDG3, less research has focused on tracking spending towards this goal. We used spending estimates to measure progress in financing the priority areas of SDG3, examine the association between outcomes and financing, and identify where resource gains are most needed to achieve the SDG3 indicators for which data are available. METHODS: We estimated domestic health spending, disaggregated by source (government, out-of-pocket, and prepaid private) from 1995 to 2017 for 195 countries and territories. For disease-specific health spending, we estimated spending for HIV/AIDS and tuberculosis for 135 low-income and middle-income countries, and malaria in 106 malaria-endemic countries, from 2000 to 2017. We also estimated development assistance for health (DAH) from 1990 to 2019, by source, disbursing development agency, recipient, and health focus area, including DAH for pandemic preparedness. Finally, we estimated future health spending for 195 countries and territories from 2018 until 2030. We report all spending estimates in inflation-adjusted 2019 US$, unless otherwise stated. FINDINGS: Since the development and implementation of the SDGs in 2015, global health spending has increased, reaching $7·9 trillion (95% uncertainty interval 7·8-8·0) in 2017 and is expected to increase to $11·0 trillion (10·7-11·2) by 2030. In 2017, in low-income and middle-income countries spending on HIV/AIDS was $20·2 billion (17·0-25·0) and on tuberculosis it was $10·9 billion (10·3-11·8), and in malaria-endemic countries spending on malaria was $5·1 billion (4·9-5·4). Development assistance for health was $40·6 billion in 2019 and HIV/AIDS has been the health focus area to receive the highest contribution since 2004. In 2019, $374 million of DAH was provided for pandemic preparedness, less than 1% of
- Published
- 2020
9. The role of cardiac troponin T quantity and function in cardiac development and dilated cardiomyopathy
- Author
-
Ahmad, F, Banerjee, SK, Lage, ML, Huang, XN, Smith, SH, Saba, S, Rager, J, Conner, DA, Janczewski, AM, Tobita, K, Tinney, JP, Moskowitz, IP, Perez-Atayde, AR, Keller, BB, Mathier, MA, Shroff, SG, Seidman, CE, Seidman, JG, Ahmad, F, Banerjee, SK, Lage, ML, Huang, XN, Smith, SH, Saba, S, Rager, J, Conner, DA, Janczewski, AM, Tobita, K, Tinney, JP, Moskowitz, IP, Perez-Atayde, AR, Keller, BB, Mathier, MA, Shroff, SG, Seidman, CE, and Seidman, JG
- Abstract
Background: Hypertrophic (HCM) and dilated (DCM) cardiomyopathies results from sarcomeric protein mutations, including cardiac troponin T (cTnT, TNNT2). We determined whether TNNT2 mutations cause cardiomyopathies by altering cTnT function or quantity; whether the severity of DCM is related to the ratio of mutant to wildtype cTnT; whether Ca2+ desensitization occurs in DCM; and whether absence of cTnT impairs early embryonic cardiogenesis. Methods and Findings: We ablated Tnnt2 to produce heterozygous Tnnt2+/ mice, and crossbreeding produced homozygous null Tnnt2-/-embryos. We also generated transgenic mice overexpressing wildtype (TGWT) or DCM mutant (TGK210Δ) Tnnt2. Crossbreeding produced mice lacking one allele of Tnnt2, but carrying wildtype (Tnnt2+/-/TGWT) or mutant (Tnnt2+/-/TGK210Δ) transgenes. Tnnt2+/-mice relative to wildtype had significantly reduced transcript (0.82 ± 0.06 [SD] vs. 1.00 ± 0.12 arbitrary units; p = 0.025), but not protein (1.01 ± 0.20 vs. 1.00 ± 0.13 arbitrary units; p = 0.44). Tnnt2+/-mice had normal hearts (histology, mass, left ventricular end diastolic diameter [LVEDD], fractional shortening [FS]). Moreover, whereas Tnnt2+/-/ TGK210Δ mice had severe DCM, TGK210Δ mice had only mild DCM (FS 18 ± 4 vs. 29 ± 7%; p < 0.01). The difference in severity of DCM may be attributable to a greater ratio of mutant to wildtype Tnnt2 transcript in Tnnt2+/-/TGK210Δ relative to TGK210Δ mice (2.42±0.08, p = 0.03). Tnnt2+/-/TGK210Δ muscle showed Ca2+ desensitization (pCa50 = 5.34 ± 0.08 vs. 5.58 ± 0.03 at sarcomere length 1.9 μm. p<0.01), but no difference in maximum force generation. Day 9.5 Tnnt2-/-embryos had normally looped hearts, but thin ventricular walls, large pericardial effusions, noncontractile hearts, and severely disorganized sarcomeres. Conclusions: Absence of one Tnnt2 allele leads to a mild deficit in transcript but not protein, leading to a normal cardiac phenotype. DCM results from abnormal function of a mutant protein, which is associa
- Published
- 2008
10. S121 Assessment of interlobarcollateral ventilation prior to endobronchial valves treatment for severe emphysema
- Author
-
Banerjee, Sk, primary, Babar, J, additional, Balan, A, additional, and Mahadeva, R, additional
- Published
- 2013
- Full Text
- View/download PDF
11. WISP2 (wnt-1-inducible signaling parthway protein-2)
- Author
-
Banerjee, SK, primary and Banerjee, S, additional
- Published
- 2011
- Full Text
- View/download PDF
12. Amorphous Structure and Stability of Mn Implanted GeC Ferromagnetic Semiconductor
- Author
-
Sun, C, primary, Floresca, HC, additional, Wang, J, additional, Jamil, M, additional, Guchhait, S, additional, Ferrer, DA, additional, Banerjee, SK, additional, Lian, G, additional, Colombo, L, additional, and Kim, MJ, additional
- Published
- 2009
- Full Text
- View/download PDF
13. Detection of Left Ventriculer Diastolic Dysfunction (LVDD) in Asymptomatic, Normotensive, ETT Negative Newly Detected Type-2 Diabetic Patients by Doppler Echocardiography
- Author
-
Banerjee, SK, primary, Siddique, MA, primary, Ahmed, CM, primary, Jamil, AA, primary, Sarma, AK, primary, Rahman, MA, primary, Sultan, MA, primary, and Hauque, KMHSS, primary
- Published
- 2004
- Full Text
- View/download PDF
14. Coronary Arteriographic Profile in Hypertrophic Cardiomyopathy (HCM)
- Author
-
Hasan, Iqbal, primary, Haque, KMHSS, primary, Ahmed, Shaffiuddin, primary, Siddique, MA, primary, Banerjee, SK, primary, Ahasan, SA, primary, Ahamed, CM, primary, Abdullah, ABM, primary, Salim, MA, primary, Rahman, MA, primary, and Siddiqui, KN, primary
- Published
- 2004
- Full Text
- View/download PDF
15. RANDOMIZED COMPARISON BETWEEN TWO-HOURLY AND THREE-HOURLY INTRAMUSCULAR TREATMENT WITH 15(S)15 METHYL PGF2α FOR TERMINATION OF SECOND TRIMESTER PREGNANCY.
- Author
-
Anjaneyula, R, Banerjee, SK, Bhattacharya, P, Das Gupta, S, Devi, K, Kanthamani, CR, Krishna, Usha R, Padma, Rao A, Raghavan, KS, Banerjee, S K, Kanthamani, C R, and Raghavan, K S
- Abstract
In a multicentre trial, intramuscular 15(S)15 methyl PGF2α (Prostin 15M, Up-john) was tried at 2-hourly and 3-hourly intervals for induction of second trimester abortion. The time schedule was assigned randomly. Eighty-eight patients for 2-hourly schedule and 89 patients for 3-hourly schedule were recruited. Of 2-hourly 83% and of 3-hourly schedule 88.8% of the patients aborted with the treatment. The induction abortion interval was 15.9 hours in 2-hourly and 17.2 hours in 3-hourly schedule. The dose of Prostin 15M was 2.2 mg and 1.7 mg respectively. The incidence of incomplete abortion was 21.9% in 2-hourly and 27.8% in the 3-hourly. The incidence of vomiting was less in the 3-hourly schedule, however, there was no difference in the incidence of diarrhoea. [ABSTRACT FROM AUTHOR]
- Published
- 1988
- Full Text
- View/download PDF
16. Triterpenes of the stem-bark of Artocarpus chaplasha
- Author
-
Banerjee Sk, Mahato Sb, and Chakravarti Rn
- Subjects
chemistry.chemical_classification ,Stem bark ,Traditional medicine ,Plant Science ,General Medicine ,Horticulture ,Biochemistry ,Terpene ,chemistry.chemical_compound ,Artocarpus chaplasha ,chemistry ,Triterpene ,Molecular Biology ,Lupeol - Abstract
From the stem-bark of Artocarpus chaplasha lupeol acetate, cycloartenyl acetate, β-sitosterol and a new triterpene, isocycloartenol (as acetate) have been isolated. Isocycloartenol has been shown to be 9:19-cyclolanost-25-en-3β-ol(I).
- Published
- 1971
17. Reactions in high boiling solvent—II
- Author
-
Banerjee Sk, Mahato Sb, and Chakravarti Rn
- Subjects
chemistry.chemical_classification ,Allylic rearrangement ,Double bond ,Organic Chemistry ,Photochemistry ,Biochemistry ,Medicinal chemistry ,Raney nickel ,Solvent ,chemistry.chemical_compound ,chemistry ,Hydrogenolysis ,Boiling ,Drug Discovery ,Dehydrogenation ,Saturation (chemistry) - Abstract
The effect of Raney nickel on triterpenoids in boiling p-cymene has been studied. The following three different types of reactions have been observed: (a) dehydrogenation (oxidation) of the 3-OH group, (b) saturation of the easily reducible double bond, and (c) shifting of the double bond to an adjacent position as in allylic shift. The shift is of reversible nature. A 3-hydroxytriterpenehydrochloride is converted to 3-keto-triterpene by this reaction, the Cl atom being removed by hydrogenolysis. A mechanism is also proposed.
- Published
- 1971
18. RANDOMIZED COMPARISON BETWEEN TWO‐HOURLY AND THREE‐HOURLY INTRAMUSCULAR TREATMENT WITH 15(S)15 METHYL PGF2αFOR TERMINATION OF SECOND TRIMESTER PREGNANCY
- Author
-
Anjaneyula, R, Banerjee, SK, Bhattacharya, P, Das Gupta, S, Devi, K, Kanthamani, CR, Krishna, Usha R, Padma, Rao A, and Raghavan, KS
- Abstract
In a multicentre trial, intramuscular 15(S)15 methyl PGF2α(Prostin 15M, Up‐john) was tried at 2‐hourly and 3‐hourly intervals for induction of second trimester abortion. The time schedule was assigned randomly. Eighty‐eight patients for 2‐hourly schedule and 89 patients for 3‐hourly schedule were recruited. Of 2‐hourly 83% and of 3‐hourly schedule 88.8% of the patients aborted with the treatment. The induction abortion interval was 15.9 hours in 2‐hourly and 17.2 hours in 3‐hourly schedule. The dose of Prostin 15M was 2.2 mg and 1.7 mg respectively. The incidence of incomplete abortion was 21.9% in 2‐hourly and 27.8% in the 3‐hourly. The incidence of vomiting was less in the 3‐hourly schedule, however, there was no difference in the incidence of diarrhoea.
- Published
- 1988
- Full Text
- View/download PDF
19. DERATED CAPACITY STATES OF A LARGE THERMAL GENERATING-UNIT
- Author
-
BANERJEE, SK and REDDI, BR
- Published
- 1983
20. RELIABILITY CALCULATIONS FOR ELECTRICAL TRANSMISSION-SYSTEMS ON THE BASIS OF MEAN FAILURE INDEXES
- Author
-
BANERJEE, SK and REDDI, BR
- Published
- 1983
21. DIRECT METHOD TO CALCULATE FREQUENCY AND DURATION OF FAILURES FOR LARGE NETWORKS
- Author
-
KHAN, NM, RAJAMANI, K, and BANERJEE, SK
- Published
- 1977
22. EVALUATION OF GENERATING-SYSTEM RELIABILITY INDEXES UNDER LIMITED REPAIR FACILITY
- Author
-
BANERJEE, SK and BHIDE, SD
- Published
- 1981
23. MAINTENANCE IMPROVEMENT POLICY TO OPTIMIZE SYSTEM AVAILABILITY
- Author
-
BANERJEE, SK and BHIDE, SD
- Published
- 1981
24. INTRAMUSCULAR 15(S)15 METHYL PGF2α IN THE TREATMENT OF MISSED ABORTION.
- Author
-
Banerjee, SK, Das Gupta, S, Dawn, CS, Mehta, AC, Kanthamani, CR, Krishna, Usha R, Raghavan, KS, Banerjee, S K, Dawn, C S, Mehta, A C, Kanthamani, C R, and Raghavan, K S
- Abstract
Intramuscular 15(S)15 methyl PGF2α (Prostin 15M, Upjohn) was used for induction of labour in cases of missed abortion and intra-uterine fetal death. The patients received premedication to control the gastrointestinal side effects. Prostin 15M was given at a dose of 250 µg every three hours and escalated whenever required. The trial was interrupted in two out of 83 patients. Altogether 75 patients (92.6%) expelled the fetus with the treatment. The mean induction abortion interval was 14.7 hours. The primigravidae had a longer (18.2 hrs) interval than the multigravidae (13.8 hrs). The mean number of episodes of vomiting was 2.9 and of diarrhoea 3.5 per patient and treatment. [ABSTRACT FROM AUTHOR]
- Published
- 1988
- Full Text
- View/download PDF
25. Effect of light and darkness on the hypothalamo-neurohypophyseal system of the garden lizard, Calotes versicolor
- Author
-
Banerjee Sk
- Subjects
Pharmacology ,Hypothalamo-Hypophyseal System ,Light ,Neurosecretion ,Lizards ,Cell Biology ,Biology ,Darkness ,Cellular and Molecular Neuroscience ,Pituitary Hormones ,Garden lizard ,Pituitary Gland ,Botany ,Molecular Medicine ,Animals ,Calotes versicolor ,Molecular Biology - Abstract
Nous avons etudie l'effet d'une l'illumination continue ou d'une obscurite de 7 jours sur le systeme hypothalamique neurosecreteur (HNS) du lezard des jardinsCalotes versicolor. L'illumination a stimule le HNS par activation de la synthese, du transport et de la liberation de la neurohormone(s) tandis que l'obscurite a fait diminuer la quantite liberee de neurohormone de la pars nervosa.
- Published
- 1973
26. Self-association of lysozyme. Thermochemical measurements: effect of chemical modification of Trp-62, Trp-108, and Glu-35.
- Author
-
Banerjee, SK, primary, Pogolotti, A, additional, and Rupley, JA, additional
- Published
- 1975
- Full Text
- View/download PDF
27. Optical properties of lysozyme. pH and saccharide binding difference spectra.
- Author
-
Imoto, T, primary, Andrews, LJ, additional, Banerjee, SK, additional, Shrake, A, additional, Forster, LS, additional, and Rupley, JA, additional
- Published
- 1975
- Full Text
- View/download PDF
28. Reaction of N-acetylglucosamine oligosaccharides with lysozyme. Temperature, pH, and solvent deuterium isotope effects; equilbrium, steady state, and pre-steady state measurements*
- Author
-
Banerjee, SK, primary, Holler, E, additional, Hess, GP, additional, and Rupley, JA, additional
- Published
- 1975
- Full Text
- View/download PDF
29. Turkey egg white lysozyme. Free energy, enthalpy, and steady state kinetics of reaction with N-acetylglucosamine oligosaccharides.
- Author
-
Banerjee, SK, primary and Rupley, JA, additional
- Published
- 1975
- Full Text
- View/download PDF
30. INTRAMUSCULAR 15(S)15 METHYL PGF2α IN THE TREATMENT OF MISSED ABORTION
- Author
-
Banerjee, SK, primary, Das Gupta, S, additional, Dawn, CS, additional, Mehta, AC, additional, Kanthamani, CR, additional, Krishna, Usha R, additional, and Raghavan, KS, additional
- Published
- 1988
- Full Text
- View/download PDF
31. RANDOMIZED COMPARISON BETWEEN TWO‐HOURLY AND THREE‐HOURLY INTRAMUSCULAR TREATMENT WITH 15(S)15 METHYL PGF2α FOR TERMINATION OF SECOND TRIMESTER PREGNANCY
- Author
-
Anjaneyula, R, primary, Banerjee, SK, additional, Bhattacharya, P, additional, Das Gupta, S, additional, Devi, K, additional, Kanthamani, CR, additional, Krishna, Usha R, additional, Padma, Rao A, additional, and Raghavan, KS, additional
- Published
- 1988
- Full Text
- View/download PDF
32. Approaches to implementing manufacturing information systems
- Author
-
Carrie, As, primary and Banerjee, Sk, additional
- Published
- 1984
- Full Text
- View/download PDF
33. INTRAMUSCULAR 15(S)15 METHYL PGF2αIN THE TREATMENT OF MISSED ABORTION
- Author
-
Banerjee, SK, Das Gupta, S, Dawn, CS, Mehta, AC, Kanthamani, CR, Krishna, Usha R, and Raghavan, KS
- Abstract
Intramuscular 15(S)15 methyl PGF2α(Prostin 15M, Upjohn) was used for induction of labour in cases of missed abortion and intra‐uterine fetal death. The patients received premedication to control the gastrointestinal side effects. Prostin 15M was given at a dose of 250 µg every three hours and escalated whenever required. The trial was interrupted in two out of 83 patients. Altogether 75 patients (92.6%) expelled the fetus with the treatment. The mean induction abortion interval was 14.7 hours. The primigravidae had a longer (18.2 hrs) interval than the multigravidae (13.8 hrs). The mean number of episodes of vomiting was 2.9 and of diarrhoea 3.5 per patient and treatment.
- Published
- 1988
- Full Text
- View/download PDF
34. Chitosan nanoparticles and neem essential oil functionalized pullulan/gum arabic active edible biocomposites for fresh-cut guava preservation.
- Author
-
Das K, Sharma S, Kumar S, Mahajan S, Banerjee SK, and Katiyar V
- Abstract
The study demonstrates the preparation of active edible biocomposites using Pullulan (PUL) and Gum Arabic (GA), functionalized with Chitosan Nanoparticles (NCS) and Neem Essential Oil (NEO). These biocomposites addressed the issues of high hydrophilicity and poor barrier properties in packaging. The effects of varying NCS concentrations (1 %, 2 %, and 3 %) on various film properties were studied, while keeping PUL, GA, and NEO concentrations constant. The biocomposite containing NEO and 3 % NCS (PUL/GA/NCS3/NEO), significantly improved surface properties, transforming it from hydrophilic (water contact angle 55.49 ± 2.31°) to hydrophobic (115.01 ± 1.86°). Additionally, tensile strength increased by ∼12.77 MPa, elongation at break by ∼6.26 %, thermal stability (T
offset ) by ∼22.49 °C, and water vapour barrier by ∼45.95 %, alongside enhanced UV-shielding, antimicrobial and antioxidant properties. The EDX analysis confirmed the biocomposite safety, with 55.7 % carbon (C), 3.6 % nitrogen (N), and 40.8 % oxygen (O). Moreover, in vitro biocompatibility tests on Human Embryonic Kidney (HEK-293) cells indicated non-cytotoxicity, with 86.82 ± 2.28 % viability after 72 h. Furthermore, the practical application of PUL/GA/NCS3/NEO solution was tested as an edible coating material for fresh-cut guava preservation. The coated guava better maintained storage quality parameters in terms of colour, weight loss, firmness, microbiological shelf-life and antioxidant activity, under both ambient and refrigerated conditions., Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024 Elsevier B.V. All rights reserved.)- Published
- 2024
- Full Text
- View/download PDF
35. Systematic evaluations and integration of Assam indigenous Joha rice starch in intelligent packaging films for monitoring food freshness using beetroot extract.
- Author
-
Lekurwale S, Mahajan S, Banerjee SK, and Banerjee S
- Subjects
- Amylose chemistry, Amylose analysis, Permeability, Rheology, Hydrogen-Ion Concentration, Temperature, Starch chemistry, Food Packaging methods, Beta vulgaris chemistry, Oryza chemistry, Plant Extracts chemistry
- Abstract
It is becoming increasingly important to have starch sources with different physicochemical properties to meet the needs of new applications in food, packaging, bioplastic, and pharmaceutical industries. The first part of this study dealt with the isolation of starch from culturally, geographically, nutritionally esteemed, and high-yielding Assam Joha rice. Fine and uniform particle size (6.3 ± 0.09 μm), high amylose content (28 ± 1.03 %), swelling behavior, viscoelastic rheological behavior, moderate gelatinization temperature (66 ± 1.7 °C), thermostable nature, type A crystallographic pattern with high (45 ± 3.3 %) crystallinity, and suitable microbial quality make the Joha rice derived starch physico-chemically and functionally suitable for potential applications in diverse domains. The latter part of the study focuses on one of the applications of derived starch as a suitable matrix for intelligent packaging films with the incorporation of betanin-enriched beetroot extract (BRE) as a bio-based pH sensor. The addition of 1.0 % w/v BRE to the starch film (starch-BRE III) significantly increased its functionality by reducing UV-visible light transmittance and water vapor permeability, along with enhancing flexibility and hydrophobicity due to intermolecular bonding between BRE and the starch film matrix. Moreover, starch-BRE films with different BRE concentrations were successfully used to monitor the real-time freshness of white meat (chicken and fish) and Indian cottage cheese samples. Overall, the results indicated that starch-BRE III has great potential as an intelligent packaging material for monitoring food freshness., Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have influenced the work reported in this study., (Copyright © 2024 Elsevier B.V. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
36. Reversal of carbapenem resistance in Pseudomonas aeruginosa by camelid single domain antibody fragment (VHH) against the C4-dicarboxylate transporter.
- Author
-
Nagraj AK, Shukla M, Kulkarni M, Patil P, Borgave M, and Banerjee SK
- Subjects
- Animals, Mice, Microbial Sensitivity Tests, Camelids, New World, Drug Resistance, Bacterial, Pseudomonas aeruginosa drug effects, Carbapenems pharmacology, Anti-Bacterial Agents pharmacology, Pseudomonas Infections drug therapy, Pseudomonas Infections microbiology, Single-Domain Antibodies pharmacology
- Abstract
Antimicrobial resistance is emerging as the new healthcare crisis necessitating the development of newer classes of drugs using non-traditional approaches. Pseudomonas aeruginosa, one of the most common pathogens involved in nosocomial infections, is extremely difficult to treat even with the last resort frontline drug, the carbapenems. As the pathogen has the ability to acquire resistance to new small-molecule antibiotics, being deployed, a novel biological approach has been tried using antibody fragments in combination with carbapenems and β-lactams as adjunct therapy for an enduring solution to the problem. In this study, we developed a camelid antibody fragment (VHH) library against P. aeruginosa and isolated a highly potent hit, PsC23. Mass spectrometry identified the target to be a component of the C4-dicarboxylate transporter that feeds metabolites to the glyoxylate shunt particularly under conditions of oxidative stress. PsC23 is bacteriostatic at a concentration of 1.66 µM (25 µg ml
-1 ) and shows a synergistic effect with both the classes of drugs at an effective concentration of 100-200 nM (1.5-3.0 µg ml-1 ) when co administered with them. In combination with meropenem the VHH completely cleared the infection from a neutropenic mouse with a carbapenem-resistant P. aeruginosa systemic infection. Blocking the glyoxylate shunt by PsC23 resulted in disruption of energy transduction due to a respiratory shift to the oxygen-depleted TCA cycle causing inhibition of efflux and increased free radical generation from carbapenems and β-lactams exerting a strong bactericidal effect that reversed the resistance to multiple unrelated drugs., (© 2024. The Author(s), under exclusive licence to the Japan Antibiotics Research Association.)- Published
- 2024
- Full Text
- View/download PDF
37. Paricalcitol attenuates oxidative stress and inflammatory response in the liver of NAFLD rats by regulating FOXO3a and NFκB acetylation.
- Author
-
Malladi N, Lahamge D, Somwanshi BS, Tiwari V, Deshmukh K, Balani JK, Chakraborty S, Alam MJ, and Banerjee SK
- Subjects
- Animals, Acetylation drug effects, Humans, Male, Rats, Hep G2 Cells, Inflammation metabolism, Sirtuin 1 metabolism, Diet, High-Fat adverse effects, Rats, Sprague-Dawley, Sirtuins, Non-alcoholic Fatty Liver Disease metabolism, Non-alcoholic Fatty Liver Disease drug therapy, Oxidative Stress drug effects, Forkhead Box Protein O3 metabolism, Forkhead Box Protein O3 genetics, NF-kappa B metabolism, Ergocalciferols pharmacology, Ergocalciferols therapeutic use, Liver metabolism, Liver drug effects
- Abstract
The lack of therapeutics along with complex pathophysiology made non-alcoholic fatty liver disease (NAFLD) a research hotspot. Studies showed that the deficiency of Vitamin D plays a vital role in NAFLD pathogenesis. While several research studies focused on vitamin D supplementation in NAFLD, there is still a need to understand the regulatory mechanism of direct vitamin D receptor activation in NAFLD. In the present study, we explored the role of direct Vitamin D receptor activation using paricalcitol in choline-deficient high-fat diet-induced NAFLD rat liver and its modulation on protein acetylation. Our results showed that paricalcitol administration significantly reduced the fat accumulation in HepG2 cells and the liver of NAFLD rats. Paricalcitol attenuated the elevated serum level of alanine transaminase, aspartate transaminase, insulin, low-density lipoprotein, triglyceride, and increased high-density lipoprotein in NAFLD rats. Paricalcitol significantly decreased the increased total protein acetylation by enhancing the SIRT1 and SIRT3 expression in NAFLD liver. Further, the study revealed that paricalcitol reduced the acetylation of NFκB and FOXO3a in NAFLD liver along with a decrease in the mRNA expression of IL1β, NFκB, TNFα, and increased catalase and MnSOD. Moreover, total antioxidant activity, glutathione, and catalase were also elevated, whereas lipid peroxidation, myeloperoxidase, and reactive oxygen species levels were significantly decreased in the liver of NAFLD after paricalcitol administration. The study concludes that the downregulation of SIRT1 and SIRT3 in NAFLD liver was associated with an increased acetylated NFκB and FOXO3a. Paricalcitol effectively reversed hepatic inflammation and oxidative stress in NAFLD rats through transcriptional regulation of NFκB and FOXO3a, respectively, by inhibiting their acetylation., Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024 Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
38. Correction: Knockdown of SCN5A alters metabolic-associated genes and aggravates hypertrophy in the cardiomyoblast.
- Author
-
Tariq U, Sarkar S, Malladi N, Kumar R, Bugga P, Chakraborty P, and Banerjee SK
- Published
- 2024
- Full Text
- View/download PDF
39. Glucose transporter 1 is essential for the resolution of methicillin-resistant S. aureus skin and soft tissue infections.
- Author
-
Banerjee SK, Thurlow LR, Kannan K, and Richardson AR
- Subjects
- Animals, Mice, PPAR gamma metabolism, Staphylococcal Skin Infections microbiology, Staphylococcal Skin Infections metabolism, Staphylococcal Skin Infections pathology, Staphylococcal Skin Infections drug therapy, Mice, Inbred C57BL, Macrophages metabolism, Macrophages microbiology, Staphylococcal Infections metabolism, Staphylococcal Infections microbiology, Methicillin-Resistant Staphylococcus aureus, Glucose Transporter Type 1 metabolism, Glucose Transporter Type 1 genetics, Soft Tissue Infections microbiology, Soft Tissue Infections metabolism, Soft Tissue Infections pathology
- Abstract
Skin/soft tissue infections (SSTIs) caused by methicillin-resistant Staphylococcus aureus (MRSA) pose a major healthcare burden. Distinct inflammatory and resolution phases comprise the host immune response to SSTIs. Resolution is a myeloid PPARγ-dependent anti-inflammatory phase that is essential for the clearance of MRSA. However, the signals activating PPARγ to induce resolution remain unknown. Here, we demonstrate that myeloid glucose transporter 1 (GLUT-1) is essential for the onset of resolution. MRSA-challenged macrophages are unsuccessful in generating an oxidative burst or immune radicals in the absence of GLUT-1 due to a reduction in the cellular NADPH pool. This translates in vivo as a significant reduction in lipid peroxidation products required for the activation of PPARγ in MRSA-infected mice lacking myeloid GLUT-1. Chemical induction of PPARγ during infection circumvents this GLUT-1 requirement and improves resolution. Thus, GLUT-1-dependent oxidative burst is essential for the activation of PPARγ and subsequent resolution of SSTIs., Competing Interests: Declaration of interests The authors declare no competing interests., (Copyright © 2024 The Author(s). Published by Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
40. An ex vivo human precision-cut lung slice platform provides insight into SARS-CoV-2 pathogenesis and antiviral drug efficacy.
- Author
-
Pechous RD, Malaviarachchi PA, Banerjee SK, Byrum SD, Alkam DH, Ghaffarieh A, Kurten RC, Kennedy JL, and Zhang X
- Subjects
- Humans, Immunity, Innate, COVID-19 Drug Treatment, Lung virology, Lung pathology, Lung drug effects, SARS-CoV-2 drug effects, SARS-CoV-2 physiology, Antiviral Agents pharmacology, COVID-19 virology, COVID-19 pathology, Cytokines metabolism, Virus Replication drug effects
- Abstract
Coronavirus disease 2019 (COVID-19) has claimed millions of lives since the emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and lung disease appears the primary cause of death in COVID-19 patients. However, the underlying mechanisms of COVID-19 pathogenesis remain elusive, and there is no existing model where human disease can be faithfully recapitulated and conditions for the infection process can be experimentally controlled. Herein we report the establishment of an ex vivo human precision-cut lung slice (hPCLS) platform for studying SARS-CoV-2 pathogenicity and innate immune responses, and for evaluating the efficacy of antiviral drugs against SARS-CoV-2. We show that while SARS-CoV-2 continued to replicate during the course of infection of hPCLS, infectious virus production peaked within 2 days, and rapidly declined thereafter. Although most proinflammatory cytokines examined were induced by SARS-CoV-2 infection, the degree of induction and types of cytokines varied significantly among hPCLS from individual donors. Two cytokines in particular, IP-10 and IL-8, were highly and consistently induced, suggesting a role in the pathogenesis of COVID-19. Histopathological examination revealed focal cytopathic effects late in the infection. Transcriptomic and proteomic analyses identified molecular signatures and cellular pathways that are largely consistent with the progression of COVID-19 in patients. Furthermore, we show that homoharringtonine, a natural plant alkaloid derived from Cephalotoxus fortunei , not only inhibited virus replication but also production of pro-inflammatory cytokines, and thus ameliorated the histopathological changes caused by SARS-CoV-2 infection, demonstrating the usefulness of the hPCLS platform for evaluating antiviral drugs., Importance: Here, established an ex vivo human precision-cut lung slice platform for assessing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, viral replication kinetics, innate immune response, disease progression, and antiviral drugs. Using this platform, we identified early induction of specific cytokines, especially IP-10 and IL-8, as potential predictors for severe coronavirus disease 2019 (COVID-19), and uncovered a hitherto unrecognized phenomenon that while infectious virus disappears at late times of infection, viral RNA persists and lung histopathology commences. This finding may have important clinical implications for both acute and post-acute sequelae of COVID-19. This platform recapitulates some of the characteristics of lung disease observed in severe COVID-19 patients and is therefore a useful platform for understanding mechanisms of SARS-CoV-2 pathogenesis and for evaluating the efficacy of antiviral drugs., Competing Interests: The authors declare no conflict of interest.
- Published
- 2024
- Full Text
- View/download PDF
41. Comparative Study on Clinical and Echocardiographic Findings in Ischemic Heart Disease Patients with or without Mitral Annular Calcification in a Tertiary Hospital.
- Author
-
Hoda MD, Hossain ME, Ahmed CM, Banerjee SK, Paul GK, and Fatema N
- Subjects
- Humans, Male, Female, Middle Aged, Case-Control Studies, Prospective Studies, Heart Valve Diseases diagnostic imaging, Heart Valve Diseases complications, Aged, Adult, Myocardial Ischemia diagnostic imaging, Calcinosis diagnostic imaging, Echocardiography methods, Mitral Valve diagnostic imaging, Mitral Valve pathology, Tertiary Care Centers
- Abstract
The presence of bright resonance of more than 1 mm or more cusps of the aortic valve, mitral valve or mitral annulus is termed as cardiac valve calcification. If an intense echo producing structure located at the junction of the atrioventricular groove and posterior mitral valve leaflet on Echocardiography that is Mitral annular calcification (MAC). This study was conducted to observe the association of MAC with clinical and echocardiographic findings of ischemic heart disease (IHD) and the role of trans-thoracic echocardiography to detect MAC which is a marker IHD. In this prospective, observational, case-control study, total of 100 IHD patients, 50 patients with MAC were assigned as case group and 50 patients without MAC were control group after fulfilling inclusion criteria. All the detailed history, clinical examination and relevant investigation reports of each patient were recorded in pre designed data collection sheet. MAC was detected with transthorasic echocardiography. Analysis was done to observe the association and correlation of MAC with clinical findings of IHD. Mean age of the case control was 55.16±10.73 years and control was 49.80±8.84 years. MAC was noted highest about 56.0% in between age 45 to 60 years. Eighty two percent (82.0%) of cases and 84.0% of controls were male, 18.0% of cases and 16.0% of controls were female. BMI among the MAC group 2.0% were underweight, 72.0% normal, 24.0% over weight and 2.0% were obese and among non MAC controls group 10.0% were underweight, 68.0% normal, 20.0% over weight and 2.0% were obese. Clinically among cases 14(28.0%) had Stable angina, 8(16.0%) had UA, 3(6.0%) had Non STEMI, 2(4.0%) had AMI, 2(4.0%) had Recent myocardial infarction and 21(42.0%) had OMI. Diabetes mellitus was significantly higher in the case groups (p=0.006). Significant p-value was noted in hyper-triyglyceridemia and low HDL in case group than control. Echocardiographic studies showed 52.0% of cases and 32.0% of controls had regional wall motion abnormality (RWMA). Transthorasic echocardiographically detected MAC is an independent predictor of Ischemic heart disease. The low cost, portable and radiation free nature of the ultrasound approach make MAC an attractive parameter in the ongoing search for IHD.
- Published
- 2024
42. Harnessing the combined effect of antivirulence agent trans-chalcone with bactericidal curcumin against sortase A enzyme to tackle Gram-positive bacterial infections.
- Author
-
Kumari P, Banerjee SK, Murty US, Ravichandiran V, and Mohan U
- Subjects
- Gram-Positive Bacteria drug effects, Gram-Positive Bacterial Infections drug therapy, Gram-Positive Bacterial Infections microbiology, Microbial Sensitivity Tests, Virulence drug effects, Virulence Factors metabolism, Aminoacyltransferases antagonists & inhibitors, Aminoacyltransferases metabolism, Anti-Bacterial Agents pharmacology, Anti-Bacterial Agents chemistry, Bacterial Proteins metabolism, Bacterial Proteins antagonists & inhibitors, Biofilms drug effects, Chalcone pharmacology, Chalcone chemistry, Curcumin pharmacology, Curcumin chemistry, Cysteine Endopeptidases drug effects, Cysteine Endopeptidases metabolism
- Abstract
Gram-positive bacteria are responsible for a wide range of infections in humans. In most Gram-positive bacteria, sortase A plays a significant role in attaching virulence factors to the bacteria's cell wall. These cell surface proteins play a significant role in virulence and pathogenesis. Even though antibiotics are available to treat these infections, there is a continuous search for an alternative strategy due to an increase in antibiotic resistance. Thus, using anti-sortase drugs to combat these bacterial infections may be a promising approach. Here, we describe a method for targeting Gram-positive bacterial infection by combining curcumin and trans-chalcone as sortase A inhibitors. We have used curcumin and trans-chalcone alone and in combination as a sortase A inhibitor. We have seen ~78%, ~43%, and ~94% inhibition when treated with curcumin, trans-chalcone, and a combination of both compounds, respectively. The compounds have also shown a significant effect on biofilm formation, IgG binding, protein A recruitment, and IgG deposition. We discovered that combining curcumin and trans-chalcone is more effective against Gram-positive bacteria than either compound alone. The present work demonstrated that a combination of these natural compounds could be used as an antivirulence therapy against Gram-positive bacterial infection., (© 2023. Institute of Microbiology, Academy of Sciences of the Czech Republic, v.v.i.)
- Published
- 2024
- Full Text
- View/download PDF
43. Doxorubicin induces phosphorylation of lamin A/C and loss of nuclear membrane integrity: A novel mechanism of cardiotoxicity.
- Author
-
Tiwari V, Gupta P, Malladi N, Salgar S, and Banerjee SK
- Subjects
- Animals, Phosphorylation drug effects, Rats, Cell Line, Myocytes, Cardiac metabolism, Myocytes, Cardiac drug effects, Myocytes, Cardiac pathology, Antibiotics, Antineoplastic toxicity, Male, Rats, Sprague-Dawley, Doxorubicin toxicity, Lamin Type A metabolism, Lamin Type A genetics, Nuclear Envelope metabolism, Nuclear Envelope drug effects, Cardiotoxicity metabolism, Cardiotoxicity pathology, Cardiotoxicity etiology
- Abstract
Lamin A/C, essential inner nuclear membrane proteins, have been linked to progeria, a disease of accelerated aging, and many other diseases, which include cardiac disorder. Lamin A/C mutation and its phosphorylation are associated with altering nuclear shape and size. The role of lamin A/C in regulating normal cardiac function was reported earlier. In the present study, we hypothesized that Doxorubicin (Dox) may alter total lamin A/C expression and phosphorylation, thereby taking part in cardiac injury. An in vitro cellular injury model was generated with Dox (0.1-10.0 μM) treatment on cardiomyoblast cells (H9c2) to prove our hypothesis. Increased size and irregular (ameboid) nucleus shape were observed in H9c2 cells after Dox treatment. Similarly, we have observed a significant increase in cell death on increasing the Dox concentration. The expression of lamin A/C and its phosphorylation at serine 22 significantly decreased and increased, respectively in H9c2 cells and rat hearts after Dox exposure. Phosphorylation led to depolymerization of the lamin A/C in the inner nuclear membrane and was evidenced by their presence throughout the nucleoplasm as observed by immunocytochemistry techniques. Thinning and perforation on the walls of the nuclear membrane were observed in Dox-treated H9c2 cells. LMNA-overexpression in H9c2 protected the cells from Dox-induced cell death, reversing all changes described above. Further, improvement of lamin A/C levels was observed in Dox-treated H9c2 cells when treated with Purvalanol A, a CDK1 inhibitor and N-acetylcysteine, an antioxidant. The study provides new insight regarding Dox-induced cardiac injury with the involvement of lamin A/C and alteration of inner nuclear membrane structure., (Copyright © 2024 Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
44. Chitosan-grafted folic acid decorated one-dimensional GONS: A biocompatible drug cargo for targeted co-delivery of anticancer agents.
- Author
-
Sontakke AD, Gupta P, Banerjee SK, and Purkait MK
- Subjects
- Humans, Drug Liberation, Biocompatible Materials chemistry, Drug Delivery Systems, Cell Survival drug effects, Nanoparticles chemistry, Cell Line, Tumor, Folic Acid chemistry, Folic Acid pharmacology, Chitosan chemistry, Doxorubicin chemistry, Doxorubicin pharmacology, Drug Carriers chemistry, Antineoplastic Agents pharmacology, Antineoplastic Agents chemistry, Graphite chemistry
- Abstract
In conventional chemotherapy, the cancer cells can become highly resilient due to a phenomenon known as multi-drug resistance (MDR). The co-delivery of chemotherapeutic agents assisted with novel nanocarrier-based targeted DDS may counter the MDR issues and subsequently improve their therapeutic efficacy. In line with this, the present work deals with the development of 1D graphene oxide nanoscrolls (GONS)-based nano delivery system for co-delivery of chemosensitizer along with the chemotherapeutic agent. Herein, the 1D GONS nanocarrier was initially functionalized with chitosan (CS) biopolymer and folic acid (FA) further to enhance their biocompatibility and target-specific co-delivery. The resultant GONS-CS-FA (GCF) nanocarriers were co-loaded with doxorubicin (DOX) and caffeic acid (CA) at different weight proportions with respect to nanocarrier and drug composition. The optimum loading efficiency of 51.14 ± 1.47 % (DOX) and 49.70 ± 1.19 % (CA) was observed for GCF: drug ratio of 2.5 with drug composition of 1:1. In vitro release at pH 5 yielded ~83 % DOX and 75 % CA, compared to ~71 % DOX and 61 % CA at pH 7.4 over 7 days, suggesting a higher and targeted drug release in the cancer microenvironment. Cytotoxicity tests revealed selective apoptosis in cancer cells (A549) while maintaining cytocompatibility with normal cells (HEK293)., Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024 Elsevier B.V. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
45. Synthesis and characterization of a pH/temperature-dual responsive hydrogel with promising biocompatibility features for stimuli-responsive 5-FU delivery.
- Author
-
Suryavanshi P, Mahajan S, Banerjee SK, Seth K, and Banerjee S
- Subjects
- Hydrogen-Ion Concentration, Animals, Humans, Drug Liberation, Mice, Drug Carriers chemistry, Drug Carriers chemical synthesis, Drug Delivery Systems, Fluorouracil pharmacology, Fluorouracil chemistry, Hydrogels chemistry, Hydrogels chemical synthesis, Hydrogels pharmacology, Temperature, Biocompatible Materials chemistry, Biocompatible Materials chemical synthesis, Biocompatible Materials pharmacology
- Abstract
The tunable properties of stimuli-responsive copolymers or hydrogels enable their application in different fields such as biomedical engineering, tissue engineering, or even drug release. Here we introduce a new PNIPAM-based triblock copolymer material comprising a controlled amount of a novel hydrophobic crosslinker 2,4'-diacryloyloxy benzophenone (DABP) and acrylic acid (AAc) to achieve lower critical solution temperature (LCST) between ambient and body temperatures. The dual stimuli-responsive p(NIPAM- co -DABP- co -AAc) triblock copolymer material and hydrogel were synthesized, and their temperature and pH-responsive behaviors were systematically investigated. The hydrogel exhibited excellent temperature and pH-responsive properties with an LCST of around 30 °C. Moreover, the synthesized copolymer has been demonstrated to be nontoxic both in vitro and in vivo . When the hydrogel was preloaded with the model drug 5-fluorouracil (5-FU), the designed hydrogel released the drug in a temperature and pH-controlled fashion. It was observed that the prepared hydrogel has the ability to entrap 5-FU, and the loading is more than 85%. In the case of temperature-controlled release, we observed almost complete release of 5-FU at lower temperatures and sustained release behavior at higher temperatures. In addition, the hydrogel matrix was able to retard the release of 5-FU in an acidic environment and selectively release 5-FU in a basic environment. By realizing how the hydrogel properties influence the release of drugs from preloaded hydrogels, it is possible to design new materials with myriad applications in the drug delivery field.
- Published
- 2024
- Full Text
- View/download PDF
46. Knockdown of SCN5A alters metabolic-associated genes and aggravates hypertrophy in the cardiomyoblast.
- Author
-
Tariq U, Sarkar S, Malladi N, Kumar R, Bugga P, Chakraborty P, and Banerjee SK
- Subjects
- Rats, Cell Line, Myocytes, Cardiac metabolism, Natriuretic Peptide, Brain genetics, Natriuretic Peptide, Brain metabolism, Animals, Gene Knockdown Techniques, Humans, Myoblasts, Cardiac metabolism, Energy Metabolism genetics, Gene Expression Regulation genetics, NAV1.5 Voltage-Gated Sodium Channel genetics, NAV1.5 Voltage-Gated Sodium Channel metabolism, Cardiomegaly genetics, Cardiomegaly metabolism, Isoproterenol pharmacology
- Abstract
SCN5A mutations have been reported to cause various cardiomyopathies in humans. Most of the SCN5A mutations causes loss of function and thereby, alters the overall cellular function. Therefore, to understand the loss of SCN5A function in cardiomyocytes, we have knocked down the SCN5A gene (SCN5A-KD) in H9c2 cells and explored the cell phenotype and molecular behaviors in the presence and absence of isoproterenol (ISO), an adrenergic receptor agonist that induces cardiac hypertrophy. Expression of several genes related to hypertrophy, inflammation, fibrosis, and energy metabolism pathways were evaluated. It was found that the mRNA expression of hypertrophy-related gene, brain (B-type) natriuretic peptide (BNP) was significantly increased in SCN5A-KD cells as compared to 'control' H9c2 cells. There was a further increase in the mRNA expressions of BNP and βMHC in SCN5A-KD cells after ISO treatment compared to their respective controls. Pro-inflammatory cytokine, tumor necrosis factor-alpha expression was significantly increased in 'SCN5A-KD' H9c2 cells. Further, metabolism-related genes like glucose transporter type 4, cluster of differentiation 36, peroxisome proliferator-activated receptor alpha, and peroxisome proliferator-activated receptor-gamma were significantly elevated in the SCN5A-KD cells as compared to the control cells. Upregulation of these metabolic genes is associated with increased ATP production. The study revealed that SCN5A knock-down causes alteration of gene expression related to cardiac hypertrophy, inflammation, and energy metabolism pathways, which may promote cardiac remodelling and cardiomyopathy., (© 2024. The Author(s), under exclusive licence to Springer Nature B.V.)
- Published
- 2024
- Full Text
- View/download PDF
47. Low-Temperature Synthesis of WSe 2 by the Selenization Process under Ultrahigh Vacuum for BEOL Compatible Reconfigurable Neurons.
- Author
-
Nibhanupudi SST, Roy A, Chowdhury S, Schalip R, Coupin MJ, Matthews KC, Alam MH, Satpati B, Movva HCP, Luth CJ, Wu S, Warner JH, and Banerjee SK
- Abstract
Low-temperature large-area growth of two-dimensional (2D) transition-metal dichalcogenides (TMDs) is critical for their integration with silicon chips. Especially, if the growth temperatures can be lowered below the back-end-of-line (BEOL) processing temperatures, the Si transistors can interface with 2D devices (in the back end) to enable high-density heterogeneous circuits. Such configurations are particularly useful for neuromorphic computing applications where a dense network of neurons interacts to compute the output. In this work, we present low-temperature synthesis (400 °C) of 2D tungsten diselenide (WSe
2 ) via the selenization of the W film under ultrahigh vacuum (UHV) conditions. This simple yet effective process yields large-area, homogeneous films of 2D TMDs, as confirmed by several characterization techniques, including reflection high-energy electron diffraction, atomic force microscopy, transmission electron microscopy, and different spectroscopy methods. Memristors fabricated using the grown WSe2 film are leveraged to realize a novel compact neuron circuit that can be reconfigured to enable homeostasis.- Published
- 2024
- Full Text
- View/download PDF
48. pH-responsive targeted nanoparticles release ERK-inhibitor in the hypoxic zone and sensitize free gemcitabine in mutant K-Ras-addicted pancreatic cancer cells and mouse model.
- Author
-
Dutta D, Ray P, De A, Ghosh A, Hazra RS, Ghosh P, Banerjee S, Diaz FJ, Upadhyay SP, Quadir M, and Banerjee SK
- Subjects
- Animals, Mice, Humans, Cell Line, Tumor, Hydrogen-Ion Concentration, Carcinoma, Pancreatic Ductal drug therapy, Carcinoma, Pancreatic Ductal pathology, Carcinoma, Pancreatic Ductal genetics, Carcinoma, Pancreatic Ductal metabolism, Proto-Oncogene Proteins p21(ras) genetics, Proto-Oncogene Proteins p21(ras) metabolism, Mutation, Protein Kinase Inhibitors pharmacology, Disease Models, Animal, Tumor Microenvironment drug effects, Deoxycytidine analogs & derivatives, Deoxycytidine pharmacology, Deoxycytidine administration & dosage, Gemcitabine, Pancreatic Neoplasms drug therapy, Pancreatic Neoplasms pathology, Pancreatic Neoplasms genetics, Pancreatic Neoplasms metabolism, Nanoparticles chemistry
- Abstract
Therapeutic options for managing Pancreatic ductal adenocarcinoma (PDAC), one of the deadliest types of aggressive malignancies, are limited and disappointing. Therefore, despite suboptimal clinical effects, gemcitabine (GEM) remains the first-line chemotherapeutic drug in the clinic for PDAC treatment. The therapeutic limitations of GEM are primarily due to poor bioavailability and the development of chemoresistance resulting from the addiction of mutant-K-RAS/AKT/ERK signaling-mediated desmoplastic barriers with a hypoxic microenvironment. Several new therapeutic approaches, including nanoparticle-assisted drug delivery, are being investigated by us and others. This study used pH-responsive nanoparticles encapsulated ERK inhibitor (SCH772984) and surface functionalized with tumor-penetrating peptide, iRGD, to target PDAC tumors. We used a small molecule, SCH772984, to target ERK1 and ERK2 in PDAC and other cancer cells. This nanocarrier efficiently released ERKi in hypoxic and low-pH environments. We also found that the free-GEM, which is functionally weak when combined with nanoencapsulated ERKi, led to significant synergistic treatment outcomes in vitro and in vivo. In particular, the combination approaches significantly enhanced the GEM effect in PDAC growth inhibition and prolonged survival of the animals in a genetically engineered KPC (LSL-KrasG12D/+/LSL-Trp53R172H/+/Pdx-1-Cre) pancreatic cancer mouse model, which is not observed in a single therapy. Mechanistically, we anticipate that the GEM efficacy was increased as ERKi blocks desmoplasia by impairing the production of desmoplastic regulatory factors in PDAC cells and KPC mouse tumors. Therefore, 2nd generation ERKi (SCH 772984)-iRGD-pHNPs are vital for the cellular response to GEM and denote a promising therapeutic target in PDAC with mutant K-RAS., Competing Interests: The authors have declared that no competing interests exist., (Copyright: This is an open access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication.)
- Published
- 2024
- Full Text
- View/download PDF
49. The structure and function of lamin A/C: Special focus on cardiomyopathy and therapeutic interventions.
- Author
-
Tiwari V, Alam MJ, Bhatia M, Navya M, and Banerjee SK
- Subjects
- Humans, Lamin Type A genetics, Lamin Type A chemistry, Lamin Type A metabolism, Mutation, Polymers, Cardiomyopathies genetics, Cardiomyopathies therapy, Muscular Dystrophies genetics, Muscular Dystrophies pathology
- Abstract
Lamins are inner nuclear membrane proteins that belong to the intermediate filament family. Lamin A/C lie adjacent to the heterochromatin structure in polymer form, providing skeletal to the nucleus. Based on the localization, lamin A/C provides nuclear stability and cytoskeleton to the nucleus and modulates chromatin organization and gene expression. Besides being the structural protein making the inner nuclear membrane in polymer form, lamin A/C functions as a signalling molecule involved in gene expression as an enhancer inside the nucleus. Lamin A/C regulates various cellular pathways like autophagy and energy balance in the cytoplasm. Its expression is highly variable in differentiated tissues, higher in hard tissues like bone and muscle cells, and lower in soft tissues like the liver and brain. In muscle cells, including the heart, lamin A/C must be expressed in a balanced state. Lamin A/C mutation is linked with various diseases, such as muscular dystrophy, lipodystrophy, and cardiomyopathies. It has been observed that a good number of mutations in the LMNA gene impact cardiac activity and its function. Although several works have been published, there are still several unexplored areas left regarding the lamin A/C function and structure in the cardiovascular system and its pathological state. In this review, we focus on the structural organization, expression pattern, and function of lamin A/C, its interacting partners, and the pathophysiology associated with mutations in the lamin A/C gene, with special emphasis on cardiovascular diseases. With the recent finding on lamin A/C, we have summarized the possible therapeutic interventions to treat cardiovascular symptoms and reverse the molecular changes., Competing Interests: Declaration of competing interest The authors declare that there are no further conflicts of interest., (Copyright © 2024 Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
50. Ultra-fast switching memristors based on two-dimensional materials.
- Author
-
Teja Nibhanupudi SS, Roy A, Veksler D, Coupin M, Matthews KC, Disiena M, Ansh, Singh JV, Gearba-Dolocan IR, Warner J, Kulkarni JP, Bersuker G, and Banerjee SK
- Abstract
The ability to scale two-dimensional (2D) material thickness down to a single monolayer presents a promising opportunity to realize high-speed energy-efficient memristors. Here, we report an ultra-fast memristor fabricated using atomically thin sheets of 2D hexagonal Boron Nitride, exhibiting the shortest observed switching speed (120 ps) among 2D memristors and low switching energy (2pJ). Furthermore, we study the switching dynamics of these memristors using ultra-short (120ps-3ns) voltage pulses, a frequency range that is highly relevant in the context of modern complementary metal oxide semiconductor (CMOS) circuits. We employ statistical analysis of transient characteristics to gain insights into the memristor switching mechanism. Cycling endurance data confirms the ultra-fast switching capability of these memristors, making them attractive for next generation computing, storage, and Radio-Frequency (RF) circuit applications., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.